<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id><journal-title-group><journal-title>JAMA Network Open</journal-title></journal-title-group><issn pub-type="epub">2574-3805</issn><publisher><publisher-name>American Medical Association</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40402498</article-id><article-id pub-id-type="pmc">PMC12100453</article-id>
<article-id pub-id-type="doi">10.1001/jamanetworkopen.2025.11764</article-id><article-id pub-id-type="publisher-id">zoi250398</article-id><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="subject-area"><subject>Infectious Diseases</subject></subj-group></article-categories><title-group><article-title>Cardiac Events in Adults Hospitalized for Respiratory Syncytial Virus vs COVID-19 or Influenza</article-title><alt-title alt-title-type="headline">Cardiac Events in Adults Hospitalized for RSV vs COVID-19 or Influenza</alt-title><alt-title alt-title-type="running-head">Cardiac Events in Adults Hospitalized for RSV vs COVID-19 or Influenza</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Wee</surname><given-names>Liang En</given-names></name><degrees>MPH</degrees><xref rid="zoi250398aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi250398aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="zoi250398aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="zoi250398aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Jue Tao</given-names></name><degrees>PhD</degrees><xref rid="zoi250398aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi250398aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ho</surname><given-names>Reen Wan Li</given-names></name><degrees>BSS</degrees><xref rid="zoi250398aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chiew</surname><given-names>Calvin J.</given-names></name><degrees>MPH</degrees><xref rid="zoi250398aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi250398aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lye</surname><given-names>David Chien Boon</given-names></name><degrees>MBBS</degrees><xref rid="zoi250398aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi250398aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="zoi250398aff7" ref-type="aff">
<sup>7</sup>
</xref><xref rid="zoi250398aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tan</surname><given-names>Kelvin Bryan</given-names></name><degrees>PhD</degrees><xref rid="zoi250398aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi250398aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="zoi250398aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="zoi250398aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="zoi250398aff8" ref-type="aff">
<sup>8</sup>
</xref><xref rid="zoi250398aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib></contrib-group><aff id="zoi250398aff1"><label>1</label>National Centre for Infectious Diseases, Singapore</aff><aff id="zoi250398aff2"><label>2</label>Duke-NUS Graduate Medical School, National University of Singapore, Singapore</aff><aff id="zoi250398aff3"><label>3</label>Department of Infectious Diseases, Singapore General Hospital, Singapore</aff><aff id="zoi250398aff4"><label>4</label>Department of Infection Prevention and Epidemiology, Singapore General Hospital, Singapore</aff><aff id="zoi250398aff5"><label>5</label>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore</aff><aff id="zoi250398aff6"><label>6</label>Ministry of Health, Singapore</aff><aff id="zoi250398aff7"><label>7</label>Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore</aff><aff id="zoi250398aff8"><label>8</label>Yong Loo Lin School of Medicine, National University of Singapore, Singapore</aff><aff id="zoi250398aff9"><label>9</label>Saw Swee Hock School of Public Health, National University of Singapore, Singapore</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> March 20, 2025.</p><p content-type="published-online"><bold>Published:</bold> May 22, 2025. doi:<uri content-type="doi">10.1001/jamanetworkopen.2025.11764</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#x000a9; 2025 Wee LE et al. <italic>JAMA Network Open</italic>.</p><corresp id="zoi250398cor1"><bold>Corresponding Author:</bold> Liang En Wee, MPH, Singapore General Hospital, 20 College Rd, Singapore 169856 (<email xlink:href="ian.wee.l.e@singhealth.com.sg">ian.wee.l.e@singhealth.com.sg</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Wee had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Wee and Lim and Ms Ho contributed equally.</p><p><italic>Concept and design:</italic> Wee, Lim, Lye, Tan.</p><p><italic>Acquisition, analysis, or interpretation of data:</italic> All authors.</p><p><italic>Drafting of the manuscript:</italic> Wee, Lim, Ho, Tan.</p><p><italic>Critical review of the manuscript for important intellectual content:</italic> Wee, Lim, Chiew, Lye, Tan.</p><p><italic>Statistical analysis:</italic> Wee, Lim, Ho.</p><p><italic>Obtained funding:</italic> Wee, Tan.</p><p><italic>Administrative, technical, or material support:</italic> Ho, Chiew, Lye, Tan.</p><p><italic>Supervision:</italic> Lye, Tan.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Wee reported grants from National Medical Research Council, Singapore Clinician Scientist New Investigator Grant (grant No. CNIG24jan-0010) during the conduct of the study. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This work was supported by Clinician Scientist New Investigator Grant CNIG24jan-0010 from the National Medical Research Council, Singapore (Dr Wee).</p><p><bold>Role of the Funder/Sponsor:</bold> The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI250398-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2025-05-22T10:00"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>5</month><year>2025</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>8</volume><issue>5</issue><elocation-id>e2511764</elocation-id><history><date date-type="received"><day>20</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>Copyright 2025 Wee LE et al. <italic>JAMA Network Open</italic>.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2511764.pdf">jamanetwopen-e2511764.pdf</self-uri><self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.11764"/><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-zoi250398-1"><title>Question</title><p>What is the risk of acute cardiovascular complications in adults hospitalized for respiratory syncytial virus (RSV) vs influenza or SARS-CoV-2 Omicron infection?</p></sec><sec id="ab-zoi250398-2"><title>Findings</title><p>In this cross-sectional study comparing 32&#x02009;960 hospitalizations for RSV with hospitalizations for influenza or Omicron XBB/JN.1 COVID-19, 10.9% of unvaccinated adults hospitalized for RSV had an acute cardiovascular event. Significantly higher odds of cardiac events were observed in patients hospitalized for RSV vs those hospitalized for COVID-19 who had received boosters or those hospitalized for contemporaneous vaccine-breakthrough influenza.</p></sec><sec id="ab-zoi250398-3"><title>Meaning</title><p>Cardiac events were more frequent in unvaccinated patients hospitalized for RSV vs boosted COVID-19 or contemporaneous vaccine-breakthrough influenza; evaluating vaccination&#x02019;s role in attenuating cardiac risk in patients with respiratory viral infection is important, given availability of RSV vaccines for older adults.</p></sec></abstract><abstract abstract-type="teaser" specific-use="electronic"><p>This cross-sectional study assesses the risk of cardiovascular complications in a nationwide cohort of Singaporean adults hospitalized for respiratory syncytial virus, influenza, or COVID-19 during community transmission of Omicron XBB/JN.1 subvariants.</p></abstract><abstract><sec id="ab-zoi250398-4"><title>Importance</title><p>Respiratory viral infections (RVIs) are associated with elevated cardiovascular risk; however, less is known about cardiac complications after hospitalization for respiratory syncytial virus (RSV) vs other vaccine-preventable RVIs (COVID-19 or influenza).</p></sec><sec id="ab-zoi250398-5"><title>Objective</title><p>To compare the risk of acute cardiovascular complications in adults hospitalized for RSV vs COVID-19 or influenza.</p></sec><sec id="ab-zoi250398-6"><title>Design, Setting, and Participants</title><p>This population-based cross-sectional study, conducted before RSV vaccination rollout in Singapore, assessed all adults hospitalized for RSV or influenza (January 1, 2017, to June 30, 2024) and all adults hospitalized for COVID-19 during Omicron XBB/JN.1 transmission (January 1, 2023, to June 30, 2024).</p></sec><sec id="ab-zoi250398-7"><title>Exposure</title><p>Hospitalization for RSV, influenza (vaccinated or unvaccinated), or COVID-19 (boosted [&#x02265;3 vaccine doses] or unboosted [&#x0003c;3 vaccine doses]).</p></sec><sec id="ab-zoi250398-8"><title>Main Outcomes and Measures</title><p>Cardiovascular events during RSV, influenza, or COVID-19 hospitalization, defined as any cardiac, cerebrovascular, or thrombotic event, occurring from admission until discharge or death. Odds of any cardiovascular event (RSV vs COVID-19 or RSV vs influenza) and severe RVI (intensive care unit admission) with or without an acute cardiovascular event were estimated using multivariate logistic regression, adjusted for sociodemographic and clinical characteristics.</p></sec><sec id="ab-zoi250398-9"><title>Results</title><p>A total of 32&#x02009;960 RVI hospitalizations (mean [SD] patient age, 66.58 [18.99] years; 17&#x02009;056 [51.7%] female) were included (2148 for RSV, 14 389 for influenza, and 16 423 for COVID-19). Of the 2148 patients hospitalized for RSV, 234 (10.9%) had an acute cardiovascular event. Higher odds of any acute cardiovascular event (adjusted odds ratio [AOR], 1.31; 95% CI, 1.12-1.54) as well as other individual cardiac events were observed in RSV hospitalizations vs boosted COVID-19 (dysrhythmia: AOR, 1.52; 95% CI, 1.19-1.94; heart failure: AOR, 1.75; 95% CI, 1.30-2.35). Similarly, higher odds of any acute cardiovascular event (AOR, 1.58; 95% CI, 1.24-2.01) as well as dysrhythmias or heart failure were observed in patients hospitalized for RSV vs unboosted COVID-19. Odds of a cardiovascular event were not significantly different in RSV vs influenza, except among contemporaneous hospitalizations after the pandemic (2023-2024), where odds of heart failure (AOR, 2.09; 95% CI, 1.21-3.59) were significantly higher in RSV hospitalizations vs vaccine-breakthrough influenza hospitalizations. Occurrence of a cardiovascular event was associated with greater odds of severe RSV requiring intensive care unit admission (AOR, 2.36; 95% CI, 1.21-4.62).</p></sec><sec id="ab-zoi250398-10"><title>Conclusions and Relevance</title><p>In this cross-sectional study, 1 in 10 patients hospitalized for RSV had a concurrent acute cardiovascular event. Odds of cardiac events were significantly higher in RSV vs COVID-19 hospitalizations in both vaccine-boosted and unboosted individuals. In contemporaneous hospitalizations for RSV or influenza after the pandemic (2023-2024), odds of heart failure were significantly higher in RSV hospitalizations vs vaccine-breakthrough influenza hospitalizations. These findings suggest that patients with preexisting cardiovascular risk should consider vaccination against RVIs.</p></sec></abstract></article-meta></front><body><sec id="H1-1-ZOI250398"><title>Introduction</title><p>Respiratory viral infections (RVIs) are associated with an elevated risk of cardiovascular complications in the acute phase of infection.<sup><xref rid="zoi250398r1" ref-type="bibr">1</xref></sup> In large, population-based, electronic health record datasets, the risks of acute myocardial infarction (AMI) and cerebrovascular events were substantially elevated for up to a month after RVIs.<sup><xref rid="zoi250398r1" ref-type="bibr">1</xref></sup> Influenza, a common cause of RVI, has been associated with a 4 to 6 times elevated risk of AMI in the immediate week after infection.<sup><xref rid="zoi250398r2" ref-type="bibr">2</xref>,<xref rid="zoi250398r3" ref-type="bibr">3</xref></sup></p><p>Less is known, however, about cardiac complications after other RVIs, such as respiratory syncytial virus (RSV), despite RSV accounting for a comparable disease burden to influenza in older adults.<sup><xref rid="zoi250398r4" ref-type="bibr">4</xref></sup> Older adults with preexisting cardiac disease are at increased risk of morbidity due to RSV.<sup><xref rid="zoi250398r5" ref-type="bibr">5</xref></sup> RSV hospitalization can, in turn, be complicated by acute cardiac events, including worsening heart failure, AMI, and arrhythmias, in up to one-fifth of adult patients.<sup><xref rid="zoi250398r6" ref-type="bibr">6</xref>,<xref rid="zoi250398r7" ref-type="bibr">7</xref></sup> Given an increasing body of evidence that highlights potential benefit of vaccination against RVI in improving cardiovascular outcomes,<sup><xref rid="zoi250398r8" ref-type="bibr">8</xref></sup> comparisons between acute cardiac complications of RSV disease and other vaccine-preventable RVIs are important, given recent availability of RSV vaccines for older adults.<sup><xref rid="zoi250398r9" ref-type="bibr">9</xref>,<xref rid="zoi250398r10" ref-type="bibr">10</xref></sup> However, existing comparisons between acute cardiac complications of RSV vs other vaccine-preventable RVIs (eg, influenza and COVID-19) predated the emergence of the milder Omicron SARS-CoV-2 variant and availability of COVID-19 vaccination<sup><xref rid="zoi250398r11" ref-type="bibr">11</xref></sup> or compared RSV and influenza only,<sup><xref rid="zoi250398r12" ref-type="bibr">12</xref>,<xref rid="zoi250398r13" ref-type="bibr">13</xref></sup> limiting generalizability. We assessed the risk of cardiovascular complications in a nationwide study of Singaporean adults hospitalized for RSV, influenza, or COVID-19 during community transmission of Omicron XBB/JN.1 subvariants to better contextualize the burden of acute cardiac events in RSV vs other vaccine-preventable RVIs.</p></sec><sec id="H1-2-ZOI250398"><title>Methods</title><sec id="H2-1-ZOI250398"><title>Study Design and Participants</title><p>This population-based, cross-sectional study was conducted in Singapore, a Southeast Asian city-state. Year-round RSV transmission has been described in Singapore, given its humid and rainy tropical climate; RSV burden in older adults (aged &#x02265;65 years) is comparable to that in younger children.<sup><xref rid="zoi250398r14" ref-type="bibr">14</xref></sup> Availability of multiplex polymerase chain reaction (PCR) testing for RVIs in hospitalized patients from 2017 onward<sup><xref rid="zoi250398r15" ref-type="bibr">15</xref>,<xref rid="zoi250398r16" ref-type="bibr">16</xref></sup> allowed for surveillance of RSV in hospitalized inpatients, particularly in at-risk populations with preexisting cardiovascular disease.<sup><xref rid="zoi250398r15" ref-type="bibr">15</xref></sup> Yearly influenza vaccination is recommended for older adults, but uptake is low (&#x0003c;15%).<sup><xref rid="zoi250398r17" ref-type="bibr">17</xref></sup> Only RSV or influenza hospitalizations from January 1, 2017, to June 30, 2024 were included, given limited diagnostic testing for RSV before 2017. Because this predated availability of RSV vaccination in Singapore, all RSV hospitalizations were unvaccinated for RSV. Omicron XBB predominated community transmission of COVID-19 in Singapore from 2023 onward<sup><xref rid="zoi250398r18" ref-type="bibr">18</xref></sup>; at the end of 2023, JN.1 displaced XBB.<sup><xref rid="zoi250398r19" ref-type="bibr">19</xref></sup> COVID-19 vaccination was first made available in Singapore from December 2020 onward, with booster doses rolled out for older adults in September 2021.<sup><xref rid="zoi250398r18" ref-type="bibr">18</xref></sup> Booster vaccination uptake in older adults was high (&#x02265;90%), given public health restrictions imposed on unvaccinated individuals.<sup><xref rid="zoi250398r20" ref-type="bibr">20</xref></sup> Only COVID-19 hospitalizations during XBB/JN.1-predominant transmission from January 1, 2023, to June 30, 2024, were included to provide a more relevant comparison during endemicity. This study was performed as part of national public health research under the Infectious Diseases Act, Singapore; as such, separate ethics review by an institutional review board was not required and informed consent was waived. All data were anonymized before analysis. All results are reported according to Strengthening the Reporting of Observational Studies in Epidemiology (<ext-link xlink:href="http://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">STROBE</ext-link>) guideline.</p></sec><sec id="H2-2-ZOI250398"><title>Exposure</title><p>RSV and influenza hospitalizations among Singaporean adults 18 years or older were identified using RSV- or influenza-specific <italic>International Statistical Classification of Diseases and Related Health Problems, Tenth Revision</italic> (<italic>ICD-10</italic>) codes recorded in Mediclaims, the national health care claims database (RSV: J12.1/J20.5/J21.0/B97.4; influenza: J10.0/ J10.1/ J10.8) (eAppendix in <xref rid="note-ZOI250398-1-s" ref-type="supplementary-material">Supplement 1</xref>).<sup><xref rid="zoi250398r21" ref-type="bibr">21</xref>,<xref rid="zoi250398r22" ref-type="bibr">22</xref></sup> In Singapore, the national government-administered medical savings scheme (Medisave) and national medical insurance scheme (Medishield) can be claimed against for inpatient care at both public and private health care institutions,<sup><xref rid="zoi250398r18" ref-type="bibr">18</xref>,<xref rid="zoi250398r19" ref-type="bibr">19</xref>,<xref rid="zoi250398r20" ref-type="bibr">20</xref></sup> enabling comprehensive capture of RSV and influenza hospitalizations across different health care settings nationally.<sup><xref rid="zoi250398r22" ref-type="bibr">22</xref></sup> RSV and influenza testing in the hospital setting is incorporated into routine respiratory viral multiplex PCR panels; testing is at physician discretion.<sup><xref rid="zoi250398r16" ref-type="bibr">16</xref>,<xref rid="zoi250398r22" ref-type="bibr">22</xref></sup> For COVID-19, during Omicron XBB&#x02013;predominant transmission from 2023 onward, testing for hospitalized patients was no longer mandatory and was performed at physicians&#x02019; discretion,<sup><xref rid="zoi250398r18" ref-type="bibr">18</xref>,<xref rid="zoi250398r19" ref-type="bibr">19</xref></sup> aligned with the shift toward endemicity. Because the <italic>ICD-10</italic> code (U07.1) was not in use for discharge coding of COVID-19 hospitalizations during the study period, data on COVID-19 hospitalizations were obtained from the national registry maintained by the Ministry of Health, which contained details of all hospitalizations attributed to COVID-19 as well as all COVID-19 test results (PCR or rapid antigen tests) (eAppendix in <xref rid="note-ZOI250398-1-s" ref-type="supplementary-material">Supplement 1</xref>).<sup><xref rid="zoi250398r18" ref-type="bibr">18</xref>,<xref rid="zoi250398r19" ref-type="bibr">19</xref></sup> Coinfections, defined as concurrent RSV and influenza hospitalizations or an RSV or influenza hospitalization with a concurrent positive SARS-CoV-2 test result, were excluded.</p></sec><sec id="H2-3-ZOI250398"><title>Outcomes</title><p>Cardiovascular events during RSV, influenza, or COVID-19 hospitalization were defined as the composite of any cardiac, cerebrovascular, or thrombotic event that occurred during the period beginning at initial admission and ending at hospital discharge or patient death, whichever was earliest. Any cardiac event was defined as the composite of any dysrhythmia, ischemic heart disease, heart failure, or other cardiac event. Cerebrovascular events included ischemic or hemorrhagic stroke and transient ischemic attack. Thrombotic events included deep venous thrombosis and pulmonary embolism. Major adverse cardiovascular or cerebrovascular events (MACEs) were defined as the first incidence of AMI, stroke, heart failure, ventricular arrhythmia, or cardiac arrest. Events were identified based on <italic>ICD-10</italic> codes recorded in Mediclaims (eAppendix in <xref rid="note-ZOI250398-1-s" ref-type="supplementary-material">Supplement 1</xref>); previously, this database was used to evaluate the risk of cardiovascular events after COVID-19 hospitalization.<sup><xref rid="zoi250398r23" ref-type="bibr">23</xref>,<xref rid="zoi250398r24" ref-type="bibr">24</xref></sup> We further evaluated whether occurrence of a cardiovascular event was associated with greater severity of RSV, influenza, or COVID-19; severity was defined as an intensive care unit (ICU) admission. COVID-19 hospitalizations were stratified by receipt of booster doses (boosted COVID-19 [&#x02265;3 vaccine doses] vs unboosted COVID-19 [&#x0003c;3 vaccine doses]); influenza hospitalizations were stratified by vaccination status, with individuals receiving seasonal influenza vaccination less than 365 days before hospitalization considered vaccinated. Vaccination status for COVID-19 and influenza was determined through linkage with the National Immunization Registry. RSV vaccines were only approved by local regulatory authorities in mid-2024; thus, all RSV hospitalizations included in this study occurred in individuals not previously vaccinated for RSV.</p></sec><sec id="H2-4-ZOI250398"><title>Covariates</title><p>The following covariates were incorporated and defined using information extracted from Ministry of Health databases: demographics (age, sex, and ethnicity, including Chinese, Malay, or other [Indian ethnicity, mixed ethnicity, or other ethnicities, such as Eurasian or Arab]), comorbidity burden (Charlson Comorbidity Index), socioeconomic status, immunocompromised status, and preexisting cardiac history, diabetes, or dyslipidemia. Information on ethnicity was collected to determine whether interethnic differences in risk of cardiovascular events existed, given the multiethnic nature of the Singaporean population. Socioeconomic status was classified by housing type.<sup><xref rid="zoi250398r20" ref-type="bibr">20</xref></sup> Information on medical comorbidities and immunocompromised status was based on diagnosis codes recorded in Mediclaims (eAppendix in <xref rid="note-ZOI250398-1-s" ref-type="supplementary-material">Supplement 1</xref>).<sup><xref rid="zoi250398r18" ref-type="bibr">18</xref>,<xref rid="zoi250398r19" ref-type="bibr">19</xref></sup></p></sec><sec id="H2-5-ZOI250398"><title>Statistical Analysis</title><p>Descriptive statistics are reported as numbers (percentages) for categorical data, means (SDs) for parametric continuous data, and medians (IQRs) for skewed data. To contrast the burden of acute cardiovascular events in RSV disease compared with COVID-19 and influenza, we report both the unweighted prevalence of cardiovascular events and weighted prevalences; weighting was estimated from generalized, boosted, model-based propensity scores.<sup><xref rid="zoi250398r25" ref-type="bibr">25</xref></sup> Odds of any cardiovascular event (composite and individual events) during hospitalization for RVI (RSV vs COVID-19 and RSV vs influenza) and odds of severe RVI (requiring ICU admission) with and without an acute cardiovascular event were estimated using multivariate logistic regression, adjusted for all available covariates (sociodemographic and clinical characteristics). Age was treated as a continuous variable in the main regression analyses.</p><p>The following sensitivity analyses were performed. First, we restricted analyses to adults 60 years or older for whom RSV vaccines are indicated. Second, to account for the possibility that testing patterns for RVI in hospitalized patients may have changed after the COVID-19 pandemic, we compared acute cardiac events across contemporaneous RSV, COVID-19, and influenza hospitalizations (January 1, 2023, to June 30, 2024). Third, only PCR-confirmed COVID-19 cases were included, excluding rapid antigen test&#x02013;positive cases without corresponding PCR to exclude the possibility that PCR testing might have been differentially used in severe COVID-19 cases. For sensitivity analyses, both unweighted prevalence and weighted prevalence of cardiovascular events, as well as odds of any composite or individual cardiovascular event, were estimated using the same methods as that of the main analysis, with weights recalculated for the subgroup of RVI hospitalizations incorporated in that specific sensitivity analysis. Analyses were conducted using R software, version 4.3.1 (R Foundation for Statistical Computing), and a 95% CI that excluded 1 was taken as the threshold for statistical significance. Correction for multiple comparisons was not made when analyzing each of the separate outcomes in addition to the composite outcome.</p></sec></sec><sec id="H1-3-ZOI250398"><title>Results</title><p>A total of 32&#x02009;960 Singaporean adults (mean [SD] patient age, 66.58 [18.99] years; 17 056 [51.7%] female and 15 904 [48.3%] male) hospitalized for RSV, influenza, or COVID-19 were included, after excluding coinfections (<xref rid="zoi250398f1" ref-type="fig">Figure</xref>). A total of 21&#x02009;009 (63.7%) had at least 1 comorbidity, 6425 (19.5%) had preexisting cardiovascular disease, and 11 593 (35.2%) had diabetes (<xref rid="zoi250398t1" ref-type="table">Table 1</xref>). Only 1037 RVI hospitalizations (3.2%) required ICU admission. In total, 2148 adults were hospitalized for RSV and 14&#x02009;389 adults were hospitalized for influenza from January 1, 2017, to June 30, 2024; 16&#x02009;423 adults were hospitalized for COVID-19 in 2023 to 2024 during Omicron XBB/JN.1&#x02013;predominant transmission (<xref rid="zoi250398f1" ref-type="fig">Figure</xref>).</p><fig position="float" id="zoi250398f1" fig-type="figure"><label>Figure. </label><caption><title>Adult Hospitalizations for Respiratory Syncytial Virus (RSV), Influenza, and COVID-19 With Number of Hospitalizations That Had Concurrent Cardiovascular Events </title></caption><graphic xlink:href="jamanetwopen-e2511764-g001" position="float"/></fig><table-wrap position="float" id="zoi250398t1"><label>Table 1. </label><caption><title>Sociodemographic and Clinical Characteristics of Hospitalizations for RSV, Influenza, and Omicron XBB/JN.1 SARS-CoV-2 in Singaporean Adults</title></caption><table frame="hsides" rules="groups"><col width="21.76%" span="1"/><col width="16.97%" span="1"/><col width="15.62%" span="1"/><col width="15.49%" span="1"/><col width="15.09%" span="1"/><col width="15.07%" span="1"/><thead><tr><th rowspan="3" valign="top" align="left" scope="rowgroup" colspan="1">Sociodemographic or clinical characteristic</th><th colspan="5" valign="top" align="left" scope="colgroup" rowspan="1">No. (%)<xref rid="zoi250398t1n1" ref-type="table-fn"><sup>a</sup></xref></th></tr><tr><th rowspan="2" valign="top" colspan="1" align="left" scope="rowgroup">RSV hospitalizations, 2017-2024</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Influenza hospitalizations, 2017-2024<xref rid="zoi250398t1n2" ref-type="table-fn"><sup>b</sup></xref></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Omicron XBB/JN.1 COVID-19 hospitalizations, 2023-2024<xref rid="zoi250398t1n3" ref-type="table-fn"><sup>c</sup></xref></th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Vaccinated</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Unvaccinated</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Boosted</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Unboosted</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Total No. of hospitalizations</td><td valign="top" align="left" rowspan="1" colspan="1">2148 (6.5)</td><td valign="top" align="left" rowspan="1" colspan="1">2416 (7.3)</td><td valign="top" align="left" rowspan="1" colspan="1">11&#x02009;973 (36.3)</td><td valign="top" align="left" rowspan="1" colspan="1">14&#x02009;485 (43.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1938 (5.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, mean (SD), y</td><td valign="top" align="left" rowspan="1" colspan="1">70.6 (16.8)</td><td valign="top" align="left" rowspan="1" colspan="1">68.0 (17.4)</td><td valign="top" align="left" rowspan="1" colspan="1">58.2 (20.2)</td><td valign="top" align="left" rowspan="1" colspan="1">71.8 (16.1)</td><td valign="top" align="left" rowspan="1" colspan="1">73.3 (16.9)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Age group, y</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#x0003c;60 </td><td valign="top" align="left" rowspan="1" colspan="1">454 (21.1)</td><td valign="top" align="left" rowspan="1" colspan="1">531 (22.0)</td><td valign="top" align="left" rowspan="1" colspan="1">5583 (46.6)</td><td valign="top" align="left" rowspan="1" colspan="1">2595 (17.9)</td><td valign="top" align="left" rowspan="1" colspan="1">354 (18.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 60-69</td><td valign="top" align="left" rowspan="1" colspan="1">421 (19.6)</td><td valign="top" align="left" rowspan="1" colspan="1">488 (20.2)</td><td valign="top" align="left" rowspan="1" colspan="1">2254 (18.8)</td><td valign="top" align="left" rowspan="1" colspan="1">2550 (17.6)</td><td valign="top" align="left" rowspan="1" colspan="1">301 (15.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 70-79 </td><td valign="top" align="left" rowspan="1" colspan="1">528 (24.6)</td><td valign="top" align="left" rowspan="1" colspan="1">782 (32.4)</td><td valign="top" align="left" rowspan="1" colspan="1">2258 (18.9)</td><td valign="top" align="left" rowspan="1" colspan="1">4083 (28.2)</td><td valign="top" align="left" rowspan="1" colspan="1">453 (23.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#x02265;80 </td><td valign="top" align="left" rowspan="1" colspan="1">745 (34.7)</td><td valign="top" align="left" rowspan="1" colspan="1">615 (25.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1878 (15.7)</td><td valign="top" align="left" rowspan="1" colspan="1">5257 (36.3)</td><td valign="top" align="left" rowspan="1" colspan="1">830 (42.8)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Ethnicity</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Chinese</td><td valign="top" align="left" rowspan="1" colspan="1">1323 (61.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1482 (61.3)</td><td valign="top" align="left" rowspan="1" colspan="1">7006 (58.5)</td><td valign="top" align="left" rowspan="1" colspan="1">11&#x02009;042 (76.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1432 (73.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Malay</td><td valign="top" align="left" rowspan="1" colspan="1">493 (23.0)</td><td valign="top" align="left" rowspan="1" colspan="1">600 (24.8)</td><td valign="top" align="left" rowspan="1" colspan="1">2927 (24.4)</td><td valign="top" align="left" rowspan="1" colspan="1">2095 (14.5)</td><td valign="top" align="left" rowspan="1" colspan="1">247 (12.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other<xref rid="zoi250398t1n4" ref-type="table-fn"><sup>d</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">332 (15.5)</td><td valign="top" align="left" rowspan="1" colspan="1">334 (13.8)</td><td valign="top" align="left" rowspan="1" colspan="1">2040 (17.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1348 (9.3)</td><td valign="top" align="left" rowspan="1" colspan="1">259 (13.4)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Gender</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td><td valign="top" align="left" rowspan="1" colspan="1">1281 (59.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1194 (49.4)</td><td valign="top" align="left" rowspan="1" colspan="1">6534 (54.6)</td><td valign="top" align="left" rowspan="1" colspan="1">7034 (48.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1013 (52.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td><td valign="top" align="left" rowspan="1" colspan="1">867 (40.4)</td><td valign="top" align="left" rowspan="1" colspan="1">1222 (50.6)</td><td valign="top" align="left" rowspan="1" colspan="1">5259 (43.9)</td><td valign="top" align="left" rowspan="1" colspan="1">7454 (51.5)</td><td valign="top" align="left" rowspan="1" colspan="1">925 (47.7)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Socioeconomic status (housing type)<xref rid="zoi250398t1n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Public, 1-2 room(s)</td><td valign="top" align="left" rowspan="1" colspan="1">256 (11.9)</td><td valign="top" align="left" rowspan="1" colspan="1">287 (11.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1328 (11.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1607 (11.1)</td><td valign="top" align="left" rowspan="1" colspan="1">254 (13.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Public, 3 rooms</td><td valign="top" align="left" rowspan="1" colspan="1">464 (21.6)</td><td valign="top" align="left" rowspan="1" colspan="1">500 (20.7)</td><td valign="top" align="left" rowspan="1" colspan="1">2354 (19.7)</td><td valign="top" align="left" rowspan="1" colspan="1">3253 (22.5)</td><td valign="top" align="left" rowspan="1" colspan="1">435 (22.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Public, 4 rooms</td><td valign="top" align="left" rowspan="1" colspan="1">668 (31.1)</td><td valign="top" align="left" rowspan="1" colspan="1">808 (33.4)</td><td valign="top" align="left" rowspan="1" colspan="1">3706 (31.0)</td><td valign="top" align="left" rowspan="1" colspan="1">4476 (30.9)</td><td valign="top" align="left" rowspan="1" colspan="1">619 (31.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Public, 5 rooms</td><td valign="top" align="left" rowspan="1" colspan="1">596 (27.7)</td><td valign="top" align="left" rowspan="1" colspan="1">646 (26.7)</td><td valign="top" align="left" rowspan="1" colspan="1">3735 (31.2)</td><td valign="top" align="left" rowspan="1" colspan="1">3988 (27.5)</td><td valign="top" align="left" rowspan="1" colspan="1">472 (24.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Private housing</td><td valign="top" align="left" rowspan="1" colspan="1">164 (7.6)</td><td valign="top" align="left" rowspan="1" colspan="1">175 (7.2)</td><td valign="top" align="left" rowspan="1" colspan="1">850 (7.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1161 (8.0)</td><td valign="top" align="left" rowspan="1" colspan="1">158 (8.2)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Comorbidity burden<xref rid="zoi250398t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Charlson Comorbidity Index of 0</td><td valign="top" align="left" rowspan="1" colspan="1">524 (24.4)</td><td valign="top" align="left" rowspan="1" colspan="1">615 (25.5)</td><td valign="top" align="left" rowspan="1" colspan="1">6310 (52.7)</td><td valign="top" align="left" rowspan="1" colspan="1">4010 (27.7)</td><td valign="top" align="left" rowspan="1" colspan="1">492 (25.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Charlson Comorbidity Index of 1-2 (mild)</td><td valign="top" align="left" rowspan="1" colspan="1">1187 (55.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1387 (57.4)</td><td valign="top" align="left" rowspan="1" colspan="1">4654 (38.9)</td><td valign="top" align="left" rowspan="1" colspan="1">7425 (51.3)</td><td valign="top" align="left" rowspan="1" colspan="1">944 (48.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Charlson Comorbidity Index &#x02265;3 (moderate-severe)</td><td valign="top" align="left" rowspan="1" colspan="1">437 (20.3)</td><td valign="top" align="left" rowspan="1" colspan="1">414 (17.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1009 (8.4)</td><td valign="top" align="left" rowspan="1" colspan="1">3050 (21.1)</td><td valign="top" align="left" rowspan="1" colspan="1">502 (25.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Immunocompromised<xref rid="zoi250398t1n7" ref-type="table-fn"><sup>g</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">466 (21.7)</td><td valign="top" align="left" rowspan="1" colspan="1">484 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1419 (11.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2715 (18.7)</td><td valign="top" align="left" rowspan="1" colspan="1">424 (21.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Preexisting cardiac history<xref rid="zoi250398t1n8" ref-type="table-fn"><sup>h</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">568 (26.4)</td><td valign="top" align="left" rowspan="1" colspan="1">509 (21.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1454 (12.1)</td><td valign="top" align="left" rowspan="1" colspan="1">3328 (23.0)</td><td valign="top" align="left" rowspan="1" colspan="1">566 (29.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Preexisting dyslipidemia</td><td valign="top" align="left" rowspan="1" colspan="1">135 (6.3)</td><td valign="top" align="left" rowspan="1" colspan="1">143 (5.9)</td><td valign="top" align="left" rowspan="1" colspan="1">404 (3.4)</td><td valign="top" align="left" rowspan="1" colspan="1">883 (6.1)</td><td valign="top" align="left" rowspan="1" colspan="1">132 (6.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Preexisting diabetes</td><td valign="top" align="left" rowspan="1" colspan="1">831 (38.7)</td><td valign="top" align="left" rowspan="1" colspan="1">954 (39.5)</td><td valign="top" align="left" rowspan="1" colspan="1">3213 (26.8)</td><td valign="top" align="left" rowspan="1" colspan="1">5845 (40.4)</td><td valign="top" align="left" rowspan="1" colspan="1">750 (38.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Preexisting chronic lung disease</td><td valign="top" align="left" rowspan="1" colspan="1">528 (24.6)</td><td valign="top" align="left" rowspan="1" colspan="1">704 (29.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1308 (10.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1743 (12.0)</td><td valign="top" align="left" rowspan="1" colspan="1">242 (12.5)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Clinical outcomes and health care uyse</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Required ICU admission</td><td valign="top" align="left" rowspan="1" colspan="1">87 (4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">84 (3.5)</td><td valign="top" align="left" rowspan="1" colspan="1">445 (3.7)</td><td valign="top" align="left" rowspan="1" colspan="1">362 (2.5)</td><td valign="top" align="left" rowspan="1" colspan="1">59 (3.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Length of stay, median (IQR), d</td><td valign="top" align="left" rowspan="1" colspan="1">4.0 (2.0-8.0)</td><td valign="top" align="left" rowspan="1" colspan="1">4.0 (2.0-6.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3.0 (2.0-5.0)</td><td valign="top" align="left" rowspan="1" colspan="1">4.0 (2.0-8.0)</td><td valign="top" align="left" rowspan="1" colspan="1">5.0 (2.0-10.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ICU length of stay, median (IQR), d</td><td valign="top" align="left" rowspan="1" colspan="1">3.0 (2.0-5.0)</td><td valign="top" align="left" rowspan="1" colspan="1">2.5 (1.0-5.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3.0 (1.0-6.0)</td><td valign="top" align="left" rowspan="1" colspan="1">2.0 (1.0-5.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3.0 (1.0-10.0)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: ICU, intensive care unit; RSV, respiratory syncytial virus.</p><fn id="zoi250398t1n1"><label>
<sup>a</sup>
</label><p>Unless otherwise indicated.</p></fn><fn id="zoi250398t1n2"><label>
<sup>b</sup>
</label><p>Individuals who had received seasonal influenza vaccination less than 365 days before hospitalization were considered vaccinated.</p></fn><fn id="zoi250398t1n3"><label>
<sup>c</sup>
</label><p>During 2023 to 2024, community transmission of COVID-19 was dominated by various Omicron XBB subvariants and subsequently JN.1. Boosting was defined as having received at least a third messenger RNA vaccine dose 6 months or more after completion of an initial 2-dose messenger RNA primary vaccine series.</p></fn><fn id="zoi250398t1n4"><label>
<sup>d</sup>
</label><p>Including individuals of Indian ethnicity, mixed ethnicity, or other ethnicities (eg, Eurasian and Arab); categories were consolidated because individual numbers were too small for separate analysis.</p></fn><fn id="zoi250398t1n5"><label>
<sup>e</sup>
</label><p>Housing type was used as an indicator of socioeconomic status.</p></fn><fn id="zoi250398t1n6"><label>
<sup>f</sup>
</label><p>Comorbidity burden was defined using the Charlson Comorbidity Index, which consists of the following comorbidities: myocardial infarction, chronic heart failure, peripheral vascular disease, cerebrovascular accident, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, diabetes, hemiplegia, liver disease, moderate to severe renal impairment, solid tumor, leukemia, and HIV infection with AIDS.</p></fn><fn id="zoi250398t1n7"><label>
<sup>g</sup>
</label><p>Immunocompromised status was defined as presence of solid malignant neoplasm, hematologic malignant neoplasm, rheumatologic or inflammatory disorders, organ or stem cell transplant, or other intrinsic immune condition or immunodeficiency.</p></fn><fn id="zoi250398t1n8"><label>
<sup>h</sup>
</label><p>Preexisting cardiac history was defined as history of ischemic heart disease or heart failure.</p></fn></table-wrap-foot></table-wrap><p>A total of 234 RSV hospitalizations (10.9%) were associated with an acute cardiovascular event; 220 (94.1%) involved cardiac events (99 dysrhythmias, 66 heart failure episodes, and 61 ischemic heart disease episodes). Atrial fibrillation or flutter was the most common dysrhythmia, occurring in 60 of 99 patients (60.6%). Preexisting cardiac history was associated with higher odds of an acute cardiovascular event (adjusted odds ratio [AOR],&#x02009;2.53; 95% CI, 1.84-3.48) among RSV hospitalizations (eTable 1 in <xref rid="note-ZOI250398-1-s" ref-type="supplementary-material">Supplement 1</xref>) and among influenza and COVID-19 hospitalizations (eTables 2 and 3 in <xref rid="note-ZOI250398-1-s" ref-type="supplementary-material">Supplement 1</xref>). Higher odds of any acute cardiovascular event (AOR, 1.31; 95% CI, 1.12-1.54) were observed in RSV hospitalizations vs COVID-19 hospitalizations in vaccine-boosted individuals; similarly, higher odds of acute cardiovascular events (AOR, 1.58; 95% CI, 1.24-2.01) were observed in RSV hospitalizations vs COVID-19 hospitalizations in unboosted individuals. Odds of any cardiovascular event were not significantly different in RSV hospitalizations vs influenza hospitalizations stratified by vaccination status (<xref rid="zoi250398t2" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="zoi250398t2"><label>Table 2. </label><caption><title>Prevalence of Acute Cardiovascular Events (Composite) Among Hospitalization for RSV, Influenza, and Omicron XBB/JN.1 SARS-CoV-2 in Singaporean Adults</title></caption><table frame="hsides" rules="groups"><col width="12.11%" span="1"/><col width="6.06%" span="1"/><col width="7.4%" span="1"/><col width="6.81%" span="1"/><col width="8.75%" span="1"/><col width="5.42%" span="1"/><col width="8.07%" span="1"/><col width="6.78%" span="1"/><col width="9.61%" span="1"/><col width="5.68%" span="1"/><col width="7.81%" span="1"/><col width="7.69%" span="1"/><col width="7.81%" span="1"/><thead><tr><th rowspan="3" valign="top" align="left" scope="rowgroup" colspan="1">RVI</th><th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">Any cardiovascular event<xref rid="zoi250398t2n1" ref-type="table-fn"><sup>a</sup></xref></th><th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">Any cardiac event<xref rid="zoi250398t2n2" ref-type="table-fn"><sup>b</sup></xref></th><th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">Any MACE<xref rid="zoi250398t2n3" ref-type="table-fn"><sup>c</sup></xref></th></tr><tr><th rowspan="2" valign="top" colspan="1" align="left" scope="rowgroup">RSV, No. (%)</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Other RVI, No. (%) (reference)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">AOR<xref rid="zoi250398t2n5" ref-type="table-fn"><sup>e</sup></xref> (95% CI)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">RSV, No. (%)</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Other RVI, No. (%) (reference)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">AOR<xref rid="zoi250398t2n5" ref-type="table-fn"><sup>e</sup></xref> (95% CI)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">RSV, No. (%)</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Other RVI, No. (%) (reference)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">AOR<xref rid="zoi250398t2n5" ref-type="table-fn"><sup>e</sup></xref> (95% CI)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Unweighted</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Weighted<xref rid="zoi250398t2n4" ref-type="table-fn"><sup>d</sup></xref></th><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Unweighted</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Weighted<xref rid="zoi250398t2n4" ref-type="table-fn"><sup>d</sup></xref></th><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Unweighted</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Weighted<xref rid="zoi250398t2n4" ref-type="table-fn"><sup>d</sup></xref></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">RSV vs COVID-19 (reference), boosted<xref rid="zoi250398t2n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">234 (10.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1180 (8.1)</td><td valign="top" align="left" rowspan="1" colspan="1">177 (8.4)</td><td valign="top" align="left" rowspan="1" colspan="1">1.31 (1.12-1.54)</td><td valign="top" align="left" rowspan="1" colspan="1">220 (10.2)</td><td valign="top" align="left" rowspan="1" colspan="1">941 (6.5)</td><td valign="top" align="left" rowspan="1" colspan="1">146 (7.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1.52 (1.28-1.79)</td><td valign="top" align="left" rowspan="1" colspan="1">113 (5.3)</td><td valign="top" align="left" rowspan="1" colspan="1">681 (4.7)</td><td valign="top" align="left" rowspan="1" colspan="1">102 (4.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1.05 (0.84-1.31)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">RSV vs COVID-19 (reference), unboosted<xref rid="zoi250398t2n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">234 (10.9)</td><td valign="top" align="left" rowspan="1" colspan="1">158 (8.2)</td><td valign="top" align="left" rowspan="1" colspan="1">142 (7.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1.58 (1.24-2.01)</td><td valign="top" align="left" rowspan="1" colspan="1">220 (10.2)</td><td valign="top" align="left" rowspan="1" colspan="1">131 (6.8)</td><td valign="top" align="left" rowspan="1" colspan="1">111 (5.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1.93 (1.49-2.50)</td><td valign="top" align="left" rowspan="1" colspan="1">113 (5.3)</td><td valign="top" align="left" rowspan="1" colspan="1">92 (4.7)</td><td valign="top" align="left" rowspan="1" colspan="1">77 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1.33 (0.97-1.82)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">RSV vs unvaccinated influenza (reference)<xref rid="zoi250398t2n7" ref-type="table-fn"><sup>g</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">234 (10.9)</td><td valign="top" align="left" rowspan="1" colspan="1">914 (7.6)</td><td valign="top" align="left" rowspan="1" colspan="1">223 (10.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1.03 (0.87-1.21)</td><td valign="top" align="left" rowspan="1" colspan="1">220 (10.2)</td><td valign="top" align="left" rowspan="1" colspan="1">821 (6.9)</td><td valign="top" align="left" rowspan="1" colspan="1">203 (9.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1.06 (0.89-1.26)</td><td valign="top" align="left" rowspan="1" colspan="1">113 (5.3)</td><td valign="top" align="left" rowspan="1" colspan="1">421 (3.5)</td><td valign="top" align="left" rowspan="1" colspan="1">115 (5.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.95 (0.75-1.19)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">RSV vs vaccinated influenza (reference)<xref rid="zoi250398t2n7" ref-type="table-fn"><sup>g</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">234 (10.9)</td><td valign="top" align="left" rowspan="1" colspan="1">226 (9.4)</td><td valign="top" align="left" rowspan="1" colspan="1">226 (11.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.95 (0.77-1.18)</td><td valign="top" align="left" rowspan="1" colspan="1">220 (10.2)</td><td valign="top" align="left" rowspan="1" colspan="1">206 (8.5)</td><td valign="top" align="left" rowspan="1" colspan="1">207 (10.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.98 (0.78-1.23)</td><td valign="top" align="left" rowspan="1" colspan="1">113 (5.3)</td><td valign="top" align="left" rowspan="1" colspan="1">101 (4.2)</td><td valign="top" align="left" rowspan="1" colspan="1">103 (5.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (0.74-1.37)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: AOR, adjusted odds ratio; MACE, major adverse cardiovascular event; RSV, respiratory syncytial virus; RVI, respiratory viral infection.</p><fn id="zoi250398t2n1"><label>
<sup>a</sup>
</label><p>Any cardiovascular event was defined as the composite of any cardiac, cerebrovascular, or thrombotic event.</p></fn><fn id="zoi250398t2n2"><label>
<sup>b</sup>
</label><p>Any cardiac event was defined as the composite of any dysrhythmia, ischemic heart disease, heart failure, or other cardiac event.</p></fn><fn id="zoi250398t2n3"><label>
<sup>c</sup>
</label><p>MACE was defined as the first incidence of myocardial infarction, stroke, heart failure, ventricular arrhythmia, or sudden cardiovascular collapse.</p></fn><fn id="zoi250398t2n4"><label>
<sup>d</sup>
</label><p>Weighted prevalence of cardiovascular events, calculated using propensity score weighting for the following covariates: age, gender, ethnicity, socioeconomic status, comorbidity burden (Charlson Comorbidity Index), immunocompromised status, preexisting cardiac history, preexisting diabetes, and preexisting dyslipidemia, with RSV hospitalization as the reference category.</p></fn><fn id="zoi250398t2n5"><label>
<sup>e</sup>
</label><p>AOR estimated using multivariate logistic regression models, adjusting for age, gender, ethnicity, socioeconomic status, comorbidity burden (Charlson Comorbidity Index), immunocompromised status, preexisting cardiac history, preexisting diabetes, preexisting dyslipidemia, and intensive care unit admission during hospitalization for RVI. Age was treated as a continuous variable in regression analyses.</p></fn><fn id="zoi250398t2n6"><label>
<sup>f</sup>
</label><p>RSV hospitalizations were compared against hospitalizations attributed to COVID-19 in January 2023 to June 2024 (COVID-19 as the reference category); during 2023 to 2024, community transmission of COVID-19 was dominated by various Omicron XBB subvariants and subsequently JN.1. Boosting was defined as having received at least a third messenger RNA vaccine dose 6 months or more after completion of an initial 2-dose messenger RNA primary vaccine series.</p></fn><fn id="zoi250398t2n7"><label>
<sup>g</sup>
</label><p>RSV hospitalizations were compared against hospitalization attributed to influenza from January 2017 to June 2024 (influenza hospitalization as the reference category). Individuals who had received seasonal influenza vaccination less than 365 days before hospitalization were considered vaccinated.</p></fn></table-wrap-foot></table-wrap><p>For individual cardiovascular events, higher odds of dysrhythmia (AOR, 1.52; 95% CI, 1.19-1.94), heart failure (AOR, 1.75; 95% CI, 1.30-2.35), and other cardiac events, including cardiac arrest, nonischemic cardiomyopathy, myocarditis, and pericarditis (AOR, 1.63; 95% CI, 1.23-2.17) were observed in RSV hospitalizations vs COVID-19 hospitalizations in vaccine-boosted individuals. Similarly, higher odds of dysrhythmia (AOR, 1.59; 95% CI, 1.09-2.30), heart failure (AOR, 2.92; 95% CI, 1.83-4.66), and other cardiac events (AOR, 2.40; 95% CI, 1.54-3.75) were observed in RSV hospitalizations vs COVID-19 hospitalizations in unboosted individuals (<xref rid="zoi250398t3" ref-type="table">Table 3</xref>). However, lower odds of cerebrovascular events were observed in RSV hospitalizations vs vaccine-boosted COVID-19 hospitalizations (AOR, 0.28; 95% CI, 0.14-0.56). Odds of an individual cardiovascular event were not significantly different in RSV hospitalizations vs influenza hospitalizations stratified by vaccination status (<xref rid="zoi250398t3" ref-type="table">Table 3</xref>). Occurrence of any cardiovascular event (AOR, 2.36; 95% CI, 1.21-4.62), any cardiac event (AOR, 2.54; 95% CI, 1.29-4.98), any MACE (AOR, 3.15; 95% CI, 1.40-7.10), and any ischemic heart disease episode (AOR, 4.90; 95% CI,&#x02009;1.81-13.25) in an RSV hospitalization was associated with greater odds of severe RSV requiring ICU admission (<xref rid="zoi250398t4" ref-type="table">Table 4</xref>). Similarly, occurrence of cardiovascular events in influenza and COVID-19 hospitalizations was associated with greater odds of requiring ICU admission.</p><table-wrap position="float" id="zoi250398t3"><label>Table 3. </label><caption><title>Prevalence of Acute Cardiovascular Events (Individual) Among Hospitalizations for RSV, Influenza, and Omicron XBB/JN.1 SARS-CoV-2 in Singaporean Adults</title></caption><table frame="hsides" rules="groups"><col width="9.28%" span="1"/><col width="5.94%" span="1"/><col width="6.74%" span="1"/><col width="5.9%" span="1"/><col width="10.95%" span="1"/><col width="7.58%" span="1"/><col width="5.9%" span="1"/><col width="6.99%" span="1"/><col width="6.49%" span="1"/><col width="5.9%" span="1"/><col width="7.54%" span="1"/><col width="6.79%" span="1"/><col width="6.74%" span="1"/><col width="7.26%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="rowgroup" colspan="1">Acute cardiovascular event</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">RSV, No. (%)</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Boosted COVID-19 group, No. (%)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">AOR (95% CI) for RSV vs boosted COVID-19 groups<xref rid="zoi250398t3n3" ref-type="table-fn"><sup>c</sup></xref></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Unboosted COVID-19</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">AOR (95% CI) for RSV vs unboosted COVID-19<xref rid="zoi250398t3n3" ref-type="table-fn"><sup>c</sup></xref></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Vaccinated influenza</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">AOR (95% CI) for RSV vs vaccinated influenza<xref rid="zoi250398t3n3" ref-type="table-fn"><sup>c</sup></xref></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Unvaccinated influenza</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">AOR (95% CI) for RSV vs unvaccinated influenza<xref rid="zoi250398t3n3" ref-type="table-fn"><sup>c</sup></xref></th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Unweighted</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Weighted<xref rid="zoi250398t3n1" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="zoi250398t3n2" ref-type="table-fn"><sup>b</sup></xref></th><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Unweighted</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Weighted<xref rid="zoi250398t3n1" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="zoi250398t3n2" ref-type="table-fn"><sup>b</sup></xref></th><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Unweighted</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Weighted<xref rid="zoi250398t3n1" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="zoi250398t3n4" ref-type="table-fn"><sup>d</sup></xref></th><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Unweighted</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Weighted<xref rid="zoi250398t3n1" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="zoi250398t3n4" ref-type="table-fn"><sup>d</sup></xref></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Any dysrhythmia<xref rid="zoi250398t3n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">99 (4.6)</td><td valign="top" align="left" rowspan="1" colspan="1">396 (2.7)</td><td valign="top" align="left" rowspan="1" colspan="1">65 (3.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1.52 (1.19-1.94)</td><td valign="top" align="left" rowspan="1" colspan="1">61 (3.1)</td><td valign="top" align="left" rowspan="1" colspan="1">59 (3.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1.59 (1.09-2.30)</td><td valign="top" align="left" rowspan="1" colspan="1">105 (4.3)</td><td valign="top" align="left" rowspan="1" colspan="1">113 (5.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.80 (0.59-1.10)</td><td valign="top" align="left" rowspan="1" colspan="1">420 (3.5)</td><td valign="top" align="left" rowspan="1" colspan="1">100 (4.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.97 (0.76-1.24)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Any ischemic heart disease</td><td valign="top" align="left" rowspan="1" colspan="1">61 (2.8)</td><td valign="top" align="left" rowspan="1" colspan="1">405 (2.8)</td><td valign="top" align="left" rowspan="1" colspan="1">58 (2.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.99 (0.74-1.31)</td><td valign="top" align="left" rowspan="1" colspan="1">48 (2.5)</td><td valign="top" align="left" rowspan="1" colspan="1">36 (1.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1.53 (0.99-2.33)</td><td valign="top" align="left" rowspan="1" colspan="1">70 (2.9)</td><td valign="top" align="left" rowspan="1" colspan="1">62 (3.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.88 (0.61-1.29)</td><td valign="top" align="left" rowspan="1" colspan="1">255 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">64 (3.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.91 (0.67-1.24)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Any heart failure</td><td valign="top" align="left" rowspan="1" colspan="1">66 (3.1)</td><td valign="top" align="left" rowspan="1" colspan="1">223 (1.5)</td><td valign="top" align="left" rowspan="1" colspan="1">37 (1.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1.75 (1.30-2.35)</td><td valign="top" align="left" rowspan="1" colspan="1">30 (1.5)</td><td valign="top" align="left" rowspan="1" colspan="1">21 (1.1)</td><td valign="top" align="left" rowspan="1" colspan="1">2.92 (1.83-4.66)</td><td valign="top" align="left" rowspan="1" colspan="1">40 (1.7)</td><td valign="top" align="left" rowspan="1" colspan="1">45 (2.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1.38 (0.88-2.17)</td><td valign="top" align="left" rowspan="1" colspan="1">185 (1.5)</td><td valign="top" align="left" rowspan="1" colspan="1">58 (2.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1.11 (0.81-1.51)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Any other cardiac event<xref rid="zoi250398t3n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">72 (3.4)</td><td valign="top" align="left" rowspan="1" colspan="1">262 (1.8)</td><td valign="top" align="left" rowspan="1" colspan="1">43 (2.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1.63 (1.23-2.17)</td><td valign="top" align="left" rowspan="1" colspan="1">38 (2.0)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (1.4)</td><td valign="top" align="left" rowspan="1" colspan="1">2.40 (1.54-3.75)</td><td valign="top" align="left" rowspan="1" colspan="1">47 (1.9)</td><td valign="top" align="left" rowspan="1" colspan="1">51 (2.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1.33 (0.87-2.03)</td><td valign="top" align="left" rowspan="1" colspan="1">203 (1.7)</td><td valign="top" align="left" rowspan="1" colspan="1">60 (2.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1.18 (0.87-1.59)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Any thrombotic event</td><td valign="top" align="left" rowspan="1" colspan="1">7 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">73 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.67 (0.30-1.49)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (0.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.38 (0.14-1.06)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.79 (0.28-2.23)</td><td valign="top" align="left" rowspan="1" colspan="1">35 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1.03 (0.44-2.42)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Any cerebrovascular event</td><td valign="top" align="left" rowspan="1" colspan="1">9 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">199 (1.4)</td><td valign="top" align="left" rowspan="1" colspan="1">30 (1.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.28 (0.14-0.56)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">67 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (0.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.60 (0.29-1.25)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: AOR, adjusted odds ratio; NA, not applicable; RSV, respiratory syncytial virus.</p><fn id="zoi250398t3n1"><label>
<sup>a</sup>
</label><p>Weighted prevalence of cardiovascular events was calculated using propensity score weighting for the following covariates: age, gender, ethnicity, socioeconomic status, comorbidity burden (Charlson Comorbidity Index), immunocompromised status, preexisting cardiac history, preexisting diabetes, and preexisting dyslipidemia, with RSV hospitalization as the reference category.</p></fn><fn id="zoi250398t3n2"><label>
<sup>b</sup>
</label><p>Hospitalization attributed to RSV from January 2017 to June 2024 was compared against hospitalization attributed to COVID-19 from January 2023 to June 2024 (COVID-19 as the reference category); during 2023 to 2024, community transmission of COVID-19 was dominated by various Omicron XBB subvariants and subsequently JN.1. Boosting was defined as having received at least a third messenger RNA vaccine dose 6 months or more after completion of an initial 2-dose messenger RNA primary vaccine series.</p></fn><fn id="zoi250398t3n3"><label>
<sup>c</sup>
</label><p>AORs were estimated using multivariate logistic regression models, adjusting for age, gender, ethnicity, socioeconomic status, comorbidity burden (Charlson Comorbidity Index), immunocompromised status, preexisting cardiac history, preexisting diabetes, preexisting dyslipidemia, and intensive care unit admission during hospitalization for respiratory viral infection. Age was treated as a continuous variable in regression analyses.</p></fn><fn id="zoi250398t3n4"><label>
<sup>d</sup>
</label><p>RSV hospitalization was compared against hospitalization attributed to influenza from January 2017 to June 2024 (influenza hospitalization as the reference category). Individuals who had received seasonal influenza vaccination less than 365 days before hospitalization were considered vaccinated.</p></fn><fn id="zoi250398t3n5"><label>
<sup>e</sup>
</label><p>Among dysrhythmias recorded during RSV hospitalization (n&#x02009;=&#x02009;99), the most common dysrhythmia was atrial fibrillation/flutter (n&#x02009;=&#x02009;60), followed by tachycardia, unspecified (n&#x02009;=&#x02009;20) and supraventricular tachycardia (n&#x02009;=&#x02009;8). Among dysrhythmias recorded during COVID-19 hospitalization (n&#x02009;=&#x02009;457), the most common dysrhythmia was atrial fibrillation or flutter (n&#x02009;=&#x02009;271), followed by tachycardia, unspecified (n&#x02009;=&#x02009;59), supraventricular tachycardia (n&#x02009;=&#x02009;30), and bradycardia, unspecified (n&#x02009;=&#x02009;30). Among dysrhythmias recorded during influenza hospitalization (n&#x02009;=&#x02009;525), the most common dysrhythmia was atrial fibrillation or flutter (n&#x02009;=&#x02009;280), followed by tachycardia, unspecified (n&#x02009;=&#x02009;123) and supraventricular tachycardia (n&#x02009;=&#x02009;31).</p></fn><fn id="zoi250398t3n6"><label>
<sup>f</sup>
</label><p>Any other cardiac event included nonischemic cardiomyopathy, cardiac arrest, cardiogenic shock, and inflammatory heart diseases (myocarditis or pericarditis).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="zoi250398t4"><label>Table 4. </label><caption><title>Odds of ICU Admission Stratified by the Presence of an Acute Cardiovascular Event During Short-Term Hospitalizations for RSV, Influenza, and Omicron XBB/JN.1 SARS-CoV-2 in Singaporean Adults</title></caption><table frame="hsides" rules="groups"><col width="11.15%" span="1"/><col width="6.06%" span="1"/><col width="6.85%" span="1"/><col width="6.85%" span="1"/><col width="4.28%" span="1"/><col width="6%" span="1"/><col width="5.14%" span="1"/><col width="6%" span="1"/><col width="6%" span="1"/><col width="6.85%" span="1"/><col width="5.14%" span="1"/><col width="5.69%" span="1"/><col width="0.3%" span="1"/><col width="7.4%" span="1"/><col width="4.6%" span="1"/><col width="5.12%" span="1"/><col width="6.57%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="rowgroup" colspan="1">Hospitalization cause</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">ICU admission, No. (%)<xref rid="zoi250398t4n1" ref-type="table-fn"><sup>a</sup></xref></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">AOR (95% CI)<xref rid="zoi250398t4n4" ref-type="table-fn"><sup>d</sup></xref></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">ICU admission, No. (%)<xref rid="zoi250398t4n2" ref-type="table-fn"><sup>b</sup></xref></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">AOR (95% CI)<xref rid="zoi250398t4n4" ref-type="table-fn"><sup>d</sup></xref></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">ICU admission, No. (%)<xref rid="zoi250398t4n3" ref-type="table-fn"><sup>c</sup></xref></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">AOR (95% CI)<xref rid="zoi250398t4n4" ref-type="table-fn"><sup>d</sup></xref></th><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">ICU admission, No. (%)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">AOR (95% CI)<xref rid="zoi250398t4n4" ref-type="table-fn"><sup>d</sup></xref></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">ICU admission, No. (%)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">AOR (95% CI)<xref rid="zoi250398t4n4" ref-type="table-fn"><sup>d</sup></xref></th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Any CV event</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">No CV event (reference)</th><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Any cardiac event</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">No cardiac event (reference)</th><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Any MAC<xref rid="zoi250398t4n3" ref-type="table-fn"><sup>c</sup></xref></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">No MACE (reference)</th><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Any IHD event</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">No IHD event (reference)</th><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Any HF event</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">No HF event</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">RSV (2017-2024)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (8.3)</td><td valign="top" align="left" rowspan="1" colspan="1">75 (3.7)</td><td valign="top" align="left" rowspan="1" colspan="1">2.36 (1.21-4.62)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (8.7)</td><td valign="top" align="left" rowspan="1" colspan="1">75 (3.7)</td><td valign="top" align="left" rowspan="1" colspan="1">2.54 (1.29-4.98)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (10.7)</td><td valign="top" align="left" rowspan="1" colspan="1">79 (3.8)</td><td valign="top" align="left" rowspan="1" colspan="1">3.15 (1.40-7.10)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (17.1)</td><td valign="top" align="left" rowspan="1" colspan="1">81 (3.8)</td><td colspan="2" valign="top" align="left" rowspan="1">4.90 (1.81-13.25)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (8.7)</td><td valign="top" align="left" rowspan="1" colspan="1">83 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2.52 (0.88-7.23)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Unvaccinated influenza (2017-2024)<xref rid="zoi250398t4n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">78 (11.9)</td><td valign="top" align="left" rowspan="1" colspan="1">367 (3.2)</td><td valign="top" align="left" rowspan="1" colspan="1">3.60 (2.50-5.18)</td><td valign="top" align="left" rowspan="1" colspan="1">71 (12.0)</td><td valign="top" align="left" rowspan="1" colspan="1">374 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">3.48 (2.38-5.07)</td><td valign="top" align="left" rowspan="1" colspan="1">52 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1">393 (3.4)</td><td valign="top" align="left" rowspan="1" colspan="1">5.25 (3.46-7.97)</td><td valign="top" align="left" rowspan="1" colspan="1">32 (18.4)</td><td valign="top" align="left" rowspan="1" colspan="1">413 (3.5)</td><td colspan="2" valign="top" align="left" rowspan="1">4.86 (2.97-7.96)</td><td valign="top" align="left" rowspan="1" colspan="1">21 (15.7)</td><td valign="top" align="left" rowspan="1" colspan="1">424 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">4.04 (2.18-7.48)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Vaccinated influenza (2017-2024)<xref rid="zoi250398t4n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">15 (10.6)</td><td valign="top" align="left" rowspan="1" colspan="1">69 (3.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3.63 (1.81-7.28)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (11.5)</td><td valign="top" align="left" rowspan="1" colspan="1">69 (3.0)</td><td valign="top" align="left" rowspan="1" colspan="1">4.01 (1.99-8.07)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (18.5)</td><td valign="top" align="left" rowspan="1" colspan="1">72 (3.1)</td><td valign="top" align="left" rowspan="1" colspan="1">6.48 (2.94-14.30)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1">76 (3.2)</td><td colspan="2" valign="top" align="left" rowspan="1">7.49 (3.01-18.61)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (14.3)</td><td valign="top" align="left" rowspan="1" colspan="1">81 (3.4)</td><td valign="top" align="left" rowspan="1" colspan="1">2.49 (0.56-11.06)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Boosted Omicron XBB/JN.1 COVID-19 (2023-2024)<xref rid="zoi250398t4n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">106 (11.3)</td><td valign="top" align="left" rowspan="1" colspan="1">256 (1.9)</td><td valign="top" align="left" rowspan="1" colspan="1">6.44 (4.83-8.59)</td><td valign="top" align="left" rowspan="1" colspan="1">94 (12.6)</td><td valign="top" align="left" rowspan="1" colspan="1">268 (2.0)</td><td valign="top" align="left" rowspan="1" colspan="1">7.16 (5.27-9.74)</td><td valign="top" align="left" rowspan="1" colspan="1">72 (13.3)</td><td valign="top" align="left" rowspan="1" colspan="1">290 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">7.17 (5.18-9.93)</td><td valign="top" align="left" rowspan="1" colspan="1">53 (16.5)</td><td valign="top" align="left" rowspan="1" colspan="1">309 (2.2)</td><td colspan="2" valign="top" align="left" rowspan="1">7.61 (5.14-11.26)</td><td valign="top" align="left" rowspan="1" colspan="1">20 (12.0)</td><td valign="top" align="left" rowspan="1" colspan="1">342 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">5.09 (2.92-8.90)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Unboosted Omicron XBB/JN.1 COVID-19 (2023-2024) <xref rid="zoi250398t4n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">15 (12.0)</td><td valign="top" align="left" rowspan="1" colspan="1">44 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">7.07 (3.40-14.69)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (11.7)</td><td valign="top" align="left" rowspan="1" colspan="1">47 (2.6)</td><td valign="top" align="left" rowspan="1" colspan="1">5.55 (2.52-12.23)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (17.8)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (2.5)</td><td valign="top" align="left" rowspan="1" colspan="1">15.13 (6.99-32.77)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (13.5)</td><td valign="top" align="left" rowspan="1" colspan="1">54 (2.8)</td><td colspan="2" valign="top" align="left" rowspan="1">4.39 (1.37-14.07)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (15.0)</td><td valign="top" align="left" rowspan="1" colspan="1">56 (2.9)</td><td valign="top" align="left" rowspan="1" colspan="1">7.83 (1.56-39.42)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: AOR, adjusted odds ratio; CV, cardiovascular; HF, heart failure; ICU, intensive care unit; IHD, ischemic heart disease; MACE, major adverse cardiovascular event; RSV, respiratory syncytial virus.</p><fn id="zoi250398t4n1"><label>
<sup>a</sup>
</label><p>Any cardiovascular event was defined as the composite of any cardiac, cerebrovascular, or thrombotic event.</p></fn><fn id="zoi250398t4n2"><label>
<sup>b</sup>
</label><p>Any cardiac event was defined as the composite of any dysrhythmia, ischemic heart disease, heart failure, or other cardiac event.</p></fn><fn id="zoi250398t4n3"><label>
<sup>c</sup>
</label><p>MACE was defined as the first incidence of myocardial infarction, stroke, heart failure, ventricular arrhythmia, or sudden cardiovascular collapse.</p></fn><fn id="zoi250398t4n4"><label>
<sup>d</sup>
</label><p>AORs were estimated using multivariate logistic regression models, adjusting for age, gender, ethnicity, socioeconomic status, comorbidity burden (Charlson Comorbidity Index), immunocompromised status, preexisting cardiac history, preexisting diabetes, preexisting dyslipidemia, and ICU admission during hospitalization for respiratory viral infection. Age was treated as a continuous variable in regression analyses.</p></fn><fn id="zoi250398t4n5"><label>
<sup>e</sup>
</label><p>Individuals who had received seasonal influenza vaccination less than 365 days before hospitalization were considered vaccinated.</p></fn><fn id="zoi250398t4n6"><label>
<sup>f</sup>
</label><p>Boosting was defined as having received at least a third messenger RNA vaccine dose 6 months or more after completion of an initial 2-dose messenger RNA primary vaccine series.</p></fn></table-wrap-foot></table-wrap><p>In sensitivity analyses, when the population was restricted to older adults 60 years or older, comparable results were found. Demographic characteristics of RVI hospitalizations in older adults are described in eTable 4 in <xref rid="note-ZOI250398-1-s" ref-type="supplementary-material">Supplement 1</xref>. Higher odds of composite and individual cardiovascular events were observed in RSV hospitalizations vs COVID-19 in older adults (eTables 5 and 6 in <xref rid="note-ZOI250398-1-s" ref-type="supplementary-material">Supplement 1</xref>), with increased odds of ICU admission among RVI hospitalizations with a cardiovascular event (eTable 7 in <xref rid="note-ZOI250398-1-s" ref-type="supplementary-material">Supplement 1</xref>). Odds of any cardiovascular event were not significantly different between RSV and influenza hospitalizations in older adults stratified by vaccination status (eTable 5 in <xref rid="note-ZOI250398-1-s" ref-type="supplementary-material">Supplement 1</xref>). Similarly, when restricted to contemporaneous RVI hospitalizations (January 1, 2023, to June 30, 2024) in the postpandemic period (eTable 8 in <xref rid="note-ZOI250398-1-s" ref-type="supplementary-material">Supplement 1</xref>), higher odds of composite and individual cardiovascular events were observed in RSV hospitalizations vs COVID-19 (eTables 9 and 10 in <xref rid="note-ZOI250398-1-s" ref-type="supplementary-material">Supplement 1</xref>). Although odds of any cardiovascular event (composite) were not significantly different between RSV and unvaccinated influenza, odds of heart failure and other cardiac events were significantly higher in adults hospitalized after the pandemic (2023-2024) for RSV vs vaccine-breakthrough influenza (heart failure: AOR, 2.09; 95% CI, 1.21-3.59; other cardiac events: AOR, 1.94; 95% CI, 1.18-3.19) (eTable 10 in <xref rid="note-ZOI250398-1-s" ref-type="supplementary-material">Supplement 1</xref>). Odds of ICU admission were increased among contemporaneous RVI hospitalizations with a cardiovascular event (eTable 11 in <xref rid="note-ZOI250398-1-s" ref-type="supplementary-material">Supplement 1</xref>). When restricted to PCR-confirmed COVID-19 hospitalizations, higher odds of composite and individual cardiovascular events were still observed in RSV hospitalizations vs COVID-19 (eTables 12 and 13 in <xref rid="note-ZOI250398-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p></sec><sec id="H1-4-ZOI250398"><title>Discussion</title><p>In this large population-based study of hospitalizations for RSV, influenza, and COVID-19 (N&#x02009;=&#x02009;32&#x02009;960), 1 in 10 RSV hospitalizations had an acute cardiovascular event. Occurrence of any cardiovascular event or MACE was associated with greater odds of severe RVI requiring ICU admission. Higher odds of any acute cardiovascular event, dysrhythmia, heart failure, and other cardiac events but lower odds of cerebrovascular events were observed in RSV vs boosted and unboosted COVID-19 hospitalizations. Although odds of an individual cardiovascular event were not significantly different overall in RSV hospitalizations vs influenza hospitalizations stratified by vaccination status, odds of heart failure and other cardiac events were significantly higher in older adults hospitalized after the pandemic (2023-2024) for RSV vs vaccine-breakthrough influenza.</p><p>Hospitalization for RSV can be complicated by acute cardiac events. In large cross-sectional studies of hospitalized adults with RVI, an acute cardiac event was experienced in one-quarter of RSV hospitalizations<sup><xref rid="zoi250398r7" ref-type="bibr">7</xref></sup> but in only 10% of COVID-19 hospitalizations in the pre-Omicron era.<sup><xref rid="zoi250398r26" ref-type="bibr">26</xref></sup> However, the burden of acute cardiac events in RSV vs COVID-19 was not directly compared. Furthermore, restriction to the pre-Omicron period limited generalizability,<sup><xref rid="zoi250398r26" ref-type="bibr">26</xref></sup> given milder Omicron infection and subsequent availability of booster vaccination. In a multicenter US study<sup><xref rid="zoi250398r27" ref-type="bibr">27</xref></sup> conducted during Omicron-predominant transmission, although RSV disease had comparable clinical severity to that of influenza and COVID-19, the prevalence of acute cardiac events was not directly compared. RSV hospitalizations were associated with greater odds of cardiac events compared with both vaccine-boosted and unboosted COVID-19 hospitalizations in the Omicron era. This finding likely reflects milder severity of Omicron-variant infection as well as the high rate of COVID-19 vaccination uptake (&#x02265;90%) in our population, contributing to greater clinical severity of RSV vis-&#x000e0;-vis COVID-19 and thus higher risk of cardiac events. We found no significant difference in acute cardiac events between RSV and influenza hospitalizations, except in contemporaneous RSV and influenza hospitalizations after the pandemic (2023-2024), in which odds of heart failure and other cardiac events were significantly higher in RSV hospitalizations vs vaccine-breakthrough influenza but not unvaccinated influenza. This finding likely reflects the impact of influenza vaccination in mitigating severe disease during the rebound in seasonal influenza that occurred after the pandemic.<sup><xref rid="zoi250398r28" ref-type="bibr">28</xref></sup></p><p>Cardiac manifestations of RSV are hypothesized to arise directly from myocardial injury or indirectly via a postinflammatory response and increased cardiovascular strain attributed to pulmonary disease.<sup><xref rid="zoi250398r5" ref-type="bibr">5</xref></sup> Dysrhythmia was the most frequently encountered cardiac event after RSV hospitalization, with atrial fibrillation most commonly reported. Although few data exist on cardiac events after RSV infection in older adults, cardiovascular complications have been reported after pediatric RSV infection.<sup><xref rid="zoi250398r29" ref-type="bibr">29</xref>,<xref rid="zoi250398r30" ref-type="bibr">30</xref></sup> In a cohort of pediatric hospitalizations for bronchiolitis that were tested for RSV and systematically evaluated for cardiac events via 24-hour Holter monitoring and echocardiography, arrhythmias were identified in 76.5% of RSV-positive patients but in less than 5% of RSV-negative cases.<sup><xref rid="zoi250398r30" ref-type="bibr">30</xref></sup> Additional studies are needed to clarify pathophysiologic mechanisms underlying dysrhythmia, symptomatic correlation, and long-term resolution in RSV-infected adults. Increased risk of cardiac events but lower risk of cerebrovascular events in RSV hospitalizations vs COVID-19 may reflect pathogen-specific differences in extrapulmonary manifestations and tropism<sup><xref rid="zoi250398r31" ref-type="bibr">31</xref></sup>; COVID-19 is associated with increased long-term risk of cardiac and neurologic manifestations in the postacute phase of infection.<sup><xref rid="zoi250398r24" ref-type="bibr">24</xref>,<xref rid="zoi250398r32" ref-type="bibr">32</xref>,<xref rid="zoi250398r33" ref-type="bibr">33</xref></sup></p><p>Occurrence of any cardiovascular event or MACE was associated with greater odds of severe RSV requiring ICU admission. In a large cross-sectional study across a US hospital network, the already high in-hospital mortality rate of 5% for older adults with RSV-associated hospitalizations was doubled among those who experienced a concurrent acute cardiac event.<sup><xref rid="zoi250398r7" ref-type="bibr">7</xref></sup> In our population, 4% of RSV hospitalizations required ICU admission; odds of ICU admission were similarly doubled among those with a concurrent cardiovascular event. Individuals with preexisting cardiac conditions had higher odds of a concurrent acute cardiac event during RSV hospitalization. In a modeling study<sup><xref rid="zoi250398r34" ref-type="bibr">34</xref></sup> that evaluated the annual economic burden attributable to RSV among US adults, burden was highest among adults with preexisting cardiac conditions. Conversely, immunocompromised individuals and those with chronic lung disease had lower odds of a concurrent acute cardiovascular event across RSV, influenza, and COVID-19 hospitalizations. This finding may reflect earlier presentation to care and prioritization for treatment (eg, increased antiviral uptake),<sup><xref rid="zoi250398r35" ref-type="bibr">35</xref>,<xref rid="zoi250398r36" ref-type="bibr">36</xref></sup> which may potentially attenuate initial disease severity<sup><xref rid="zoi250398r37" ref-type="bibr">37</xref></sup> and thus subsequent risk of cardiovascular events, given greater awareness in these at-risk groups. Increasing awareness and vaccination uptake among adults with preexisting cardiac conditions is crucial, given effectiveness of existing influenza and COVID-19 vaccines in preventing RVI-related hospitalization and mitigating severe disease among adults with cardiac conditions,<sup><xref rid="zoi250398r38" ref-type="bibr">38</xref>,<xref rid="zoi250398r39" ref-type="bibr">39</xref></sup> high frequency of congestive heart failure among RSV and influenza hospitalizations,<sup><xref rid="zoi250398r40" ref-type="bibr">40</xref></sup> and data affirming that simultaneous administration of RSV and influenza vaccination is safe in high-risk patients with heart failure, with a low incidence of mild adverse events.<sup><xref rid="zoi250398r41" ref-type="bibr">41</xref></sup> Given recent availability of RSV vaccination, older adults with preexisting cardiac history should be prioritized for vaccination against vaccine-preventable RVIs. Patients with a prior cardiac history might also benefit from more intensive clinical evaluation and monitoring for cardiac events during RSV hospitalization in light of greater risk.</p><sec id="H2-6-ZOI250398"><title>Strengths and Limitations</title><p>The strengths of our study include use of a comprehensive electronic health record&#x02013;based health care claims database with national-level coverage to examine cardiovascular events in acute RSV, influenza, and COVID-19 hospitalizations, minimizing bias caused by loss to follow-up. Prevalence of acute cardiovascular events in RSV hospitalizations was compared against a contemporaneous control population (individuals hospitalized for influenza or COVID-19), allowing better contextualization of cardiovascular risk estimates for RSV hospitalizations vs other vaccine-preventable RVIs.</p><p>This study also has limitations. Reliance on administrative claims for ascertainment of cardiovascular events might have resulted in underreporting of milder events not affecting reimbursement, although most cardiovascular events that were evaluated in our study were serious enough to necessitate hospitalization. Mandatory reporting of COVID-19 hospitalizations may have biased toward inclusion of milder COVID-19 cases tested incidentally for SARS-CoV-2, whereas RSV and influenza hospitalizations were identified based on diagnosis codes in health care claims data and laboratory data were unavailable. However, our findings demonstrating higher odds of cardiovascular events in RSV vs COVID-19 hospitalizations remained robust when restricted to the subset of PCR-confirmed COVID-19 hospitalizations and when contemporaneous RSV and COVID-19 hospitalizations were compared. The effect of therapeutics on observed severity was not accounted for, although there is no routine treatment for RSV in adults and uptake of COVID-19 therapeutics was low (&#x0003c;5%).<sup><xref rid="zoi250398r36" ref-type="bibr">36</xref></sup> Additionally, our results may not be generalizable to other populations, particularly those with lower uptake of COVID-19 vaccination.</p></sec></sec><sec id="H1-5-ZOI250398"><title>Conclusions</title><p>In this cross-sectional study prior to RSV vaccination rollout, 1 in 10 RSV hospitalizations had a concurrent acute cardiovascular event, and odds of cardiovascular events were significantly higher in RSV hospitalizations vs COVID-19 hospitalizations in vaccine-boosted and unboosted individuals. There was no significant difference in acute cardiac events between RSV and influenza hospitalizations, except in contemporaneous RSV and influenza hospitalizations after the pandemic (2023-2024), in which odds of heart failure were significantly higher in RSV hospitalizations vs vaccine-breakthrough influenza. Evaluating vaccination&#x02019;s role in attenuating risk of cardiovascular events associated with vaccine-preventable RVIs remains important given the availability of RSV vaccines for older adults and existing vaccine skepticism during COVID-19 endemicity. Individuals with a preexisting cardiac history remain at higher risk of acute cardiac events during RSV hospitalization and should be prioritized for vaccination.</p></sec></body><back><ref-list id="REF-ZOI250398"><title>References</title><ref id="zoi250398r1"><label>1</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Davidson</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Banerjee</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Smeeth</surname>
<given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Risk of acute respiratory infection and acute cardiovascular events following acute respiratory infection among adults with increased cardiovascular risk in England between 2008 and 2018: a retrospective, population-based cohort study</article-title>. <source>Lancet Digit Health</source>. <year>2021</year>;<volume>3</volume>(<issue>12</issue>):<fpage>e773</fpage>-<lpage>e783</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2589-7500(21)00203-X</pub-id><pub-id pub-id-type="pmid">34823706</pub-id>
</mixed-citation></ref><ref id="zoi250398r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name><surname>de Boer</surname>
<given-names>AR</given-names></string-name>, <string-name><surname>Riezebos-Brilman</surname>
<given-names>A</given-names></string-name>, <string-name><surname>van Hout</surname>
<given-names>D</given-names></string-name>, <etal/></person-group>. Influenza infection and acute myocardial infarction. <source>NEJM Evid</source>. Published online June 25, <year>2024</year>. doi:<pub-id pub-id-type="doi">10.1056/EVIDoa2300361</pub-id></mixed-citation></ref><ref id="zoi250398r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Warren-Gash</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Hayward</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Hemingway</surname>
<given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study</article-title>. <source>J Infect Dis</source>. <year>2012</year>;<volume>206</volume>(<issue>11</issue>):<fpage>1652</fpage>-<lpage>1659</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jis597</pub-id><pub-id pub-id-type="pmid">23048170</pub-id>
</mixed-citation></ref><ref id="zoi250398r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Wildenbeest</surname>
<given-names>JG</given-names></string-name>, <string-name><surname>Lowe</surname>
<given-names>DM</given-names></string-name>, <string-name><surname>Standing</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Butler</surname>
<given-names>CC</given-names></string-name></person-group>. Respiratory syncytial virus infections in adults: a narrative review. <source>Lancet Respir Med</source>. <year>2024</year>;2(10):822-836. doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(24)00255-8</pub-id></mixed-citation></ref><ref id="zoi250398r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Ivey</surname>
<given-names>KS</given-names></string-name>, <string-name><surname>Edwards</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Talbot</surname>
<given-names>HK</given-names></string-name></person-group>. <article-title>Respiratory syncytial virus and associations with cardiovascular disease in adults</article-title>. <source>J Am Coll Cardiol</source>. <year>2018</year>;<volume>71</volume>(<issue>14</issue>):<fpage>1574</fpage>-<lpage>1583</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jacc.2018.02.013</pub-id><pub-id pub-id-type="pmid">29622165</pub-id>
</mixed-citation></ref><ref id="zoi250398r6"><label>6</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Anderson</surname>
<given-names>NW</given-names></string-name>, <string-name><surname>Binnicker</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Harris</surname>
<given-names>DM</given-names></string-name>, <etal/></person-group>. <article-title>Morbidity and mortality among patients with respiratory syncytial virus infection: a 2-year retrospective review</article-title>. <source>Diagn Microbiol Infect Dis</source>. <year>2016</year>;<volume>85</volume>(<issue>3</issue>):<fpage>367</fpage>-<lpage>371</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2016.02.025</pub-id><pub-id pub-id-type="pmid">27179369</pub-id>
</mixed-citation></ref><ref id="zoi250398r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Woodruff</surname>
<given-names>RC</given-names></string-name>, <string-name><surname>Melgar</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Pham</surname>
<given-names>H</given-names></string-name>, <etal/>; <collab>Respiratory Syncytial Virus Hospitalization Surveillance Network (RSV-NET)</collab></person-group>. <article-title>Acute cardiac events in hospitalized older adults with respiratory syncytial virus infection</article-title>. <source>JAMA Intern Med</source>. <year>2024</year>;<volume>184</volume>(<issue>6</issue>):<fpage>602</fpage>-<lpage>611</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamainternmed.2024.0212</pub-id><pub-id pub-id-type="pmid">38619857</pub-id>
</mixed-citation></ref><ref id="zoi250398r8"><label>8</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Rademacher</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Therre</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hinze</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Buder</surname>
<given-names>F</given-names></string-name>, <string-name><surname>B&#x000f6;hm</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Welte</surname>
<given-names>T</given-names></string-name></person-group>. <article-title>Association of respiratory infections and the impact of vaccinations on cardiovascular diseases</article-title>. <source>Eur J Prev Cardiol</source>. <year>2024</year>;<volume>31</volume>(<issue>7</issue>):<fpage>877</fpage>-<lpage>888</lpage>. doi:<pub-id pub-id-type="doi">10.1093/eurjpc/zwae016</pub-id><pub-id pub-id-type="pmid">38205961</pub-id>
</mixed-citation></ref><ref id="zoi250398r9"><label>9</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Papi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ison</surname>
<given-names>MG</given-names></string-name>, <string-name><surname>Langley</surname>
<given-names>JM</given-names></string-name>, <etal/>; <collab>AReSVi-006 Study Group</collab></person-group>. <article-title>Respiratory syncytial virus prefusion F protein vaccine in older adults</article-title>. <source>N Engl J Med</source>. <year>2023</year>;<volume>388</volume>(<issue>7</issue>):<fpage>595</fpage>-<lpage>608</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2209604</pub-id><pub-id pub-id-type="pmid">36791160</pub-id>
</mixed-citation></ref><ref id="zoi250398r10"><label>10</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Wilson</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Goswami</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Baqui</surname>
<given-names>AH</given-names></string-name>, <etal/>; <collab>ConquerRSV Study Group</collab></person-group>. <article-title>Efficacy and safety of an mRNA-based RSV preF vaccine in older adults</article-title>. <source>N Engl J Med</source>. <year>2023</year>;<volume>389</volume>(<issue>24</issue>):<fpage>2233</fpage>-<lpage>2244</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2307079</pub-id><pub-id pub-id-type="pmid">38091530</pub-id>
</mixed-citation></ref><ref id="zoi250398r11"><label>11</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Hedberg</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Karlsson Valik</surname>
<given-names>J</given-names></string-name>, <string-name><surname>van der Werff</surname>
<given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Clinical phenotypes and outcomes of SARS-CoV-2, influenza, RSV and seven other respiratory viruses: a retrospective study using complete hospital data</article-title>. <source>Thorax</source>. <year>2022</year>;<volume>77</volume>(<issue>2</issue>):<fpage>154</fpage>-<lpage>163</lpage>. doi:<pub-id pub-id-type="doi">10.1136/thoraxjnl-2021-216949</pub-id><pub-id pub-id-type="pmid">34226206</pub-id>
</mixed-citation></ref><ref id="zoi250398r12"><label>12</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Lee</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Lui</surname>
<given-names>GC</given-names></string-name>, <string-name><surname>Wong</surname>
<given-names>KT</given-names></string-name>, <etal/></person-group>. <article-title>High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections</article-title>. <source>Clin Infect Dis</source>. <year>2013</year>;<volume>57</volume>(<issue>8</issue>):<fpage>1069</fpage>-<lpage>1077</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/cit471</pub-id><pub-id pub-id-type="pmid">23876395</pub-id>
</mixed-citation></ref><ref id="zoi250398r13"><label>13</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Loubet</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Lenzi</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Valette</surname>
<given-names>M</given-names></string-name>, <etal/>; <collab>FLUVAC Study Group</collab></person-group>. <article-title>Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France</article-title>. <source>Clin Microbiol Infect</source>. <year>2017</year>;<volume>23</volume>(<issue>4</issue>):<fpage>253</fpage>-<lpage>259</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cmi.2016.11.014</pub-id><pub-id pub-id-type="pmid">27903461</pub-id>
</mixed-citation></ref><ref id="zoi250398r14"><label>14</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Ang</surname>
<given-names>LW</given-names></string-name>, <string-name><surname>Mak</surname>
<given-names>TM</given-names></string-name>, <string-name><surname>Cui</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Leo</surname>
<given-names>YS</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>VJM</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>RT</given-names></string-name></person-group>. <article-title>Characterisation of respiratory syncytial virus activity in children and adults presenting with acute respiratory illness at primary care clinics in Singapore, 2014-2018</article-title>. <source>Influenza Other Respir Viruses</source>. <year>2020</year>;<volume>14</volume>(<issue>4</issue>):<fpage>412</fpage>-<lpage>419</lpage>. doi:<pub-id pub-id-type="doi">10.1111/irv.12730</pub-id><pub-id pub-id-type="pmid">32090482</pub-id>
</mixed-citation></ref><ref id="zoi250398r15"><label>15</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Chan</surname>
<given-names>CY</given-names></string-name>, <string-name><surname>Low</surname>
<given-names>JG</given-names></string-name>, <string-name><surname>Wyone</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Oon</surname>
<given-names>LL</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>BH</given-names></string-name></person-group>. <article-title>Survey of respiratory virus in patients hospitalised for acute exacerbations of heart failure - a prospective observational study</article-title>. <source>Ann Acad Med Singap</source>. <year>2018</year>;<volume>47</volume>(<issue>11</issue>):<fpage>445</fpage>-<lpage>450</lpage>. doi:<pub-id pub-id-type="doi">10.47102/annals-acadmedsg.V47N11p445</pub-id><pub-id pub-id-type="pmid">30578423</pub-id>
</mixed-citation></ref><ref id="zoi250398r16"><label>16</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Wee</surname>
<given-names>LE</given-names></string-name>, <string-name><surname>Conceicao</surname>
<given-names>EP</given-names></string-name>, <string-name><surname>Sim</surname>
<given-names>XYJ</given-names></string-name>, <string-name><surname>Ko</surname>
<given-names>KKK</given-names></string-name>, <string-name><surname>Ling</surname>
<given-names>ML</given-names></string-name>, <string-name><surname>Venkatachalam</surname>
<given-names>I</given-names></string-name></person-group>. <article-title>Reduction in healthcare-associated respiratory viral infections during a COVID-19 outbreak</article-title>. <source>Clin Microbiol Infect</source>. <year>2020</year>;<volume>26</volume>(<issue>11</issue>):<fpage>1579</fpage>-<lpage>1581</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cmi.2020.06.027</pub-id><pub-id pub-id-type="pmid">32622953</pub-id>
</mixed-citation></ref><ref id="zoi250398r17"><label>17</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Rusli</surname>
<given-names>KDB</given-names></string-name>, <string-name><surname>Bryar</surname>
<given-names>R</given-names></string-name></person-group>. <article-title>Maximising influenza vaccination awareness and uptake among older adults in Singapore</article-title>. <source>Br J Community Nurs</source>. <year>2018</year>;<volume>23</volume>(<issue>6</issue>):<fpage>244</fpage>-<lpage>249</lpage>. doi:<pub-id pub-id-type="doi">10.12968/bjcn.2018.23.6.244</pub-id><pub-id pub-id-type="pmid">29799775</pub-id>
</mixed-citation></ref><ref id="zoi250398r18"><label>18</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Wee</surname>
<given-names>LE</given-names></string-name>, <string-name><surname>Pang</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Chiew</surname>
<given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Long-term real-world protection afforded by third mRNA doses against symptomatic severe acute respiratory syndrome coronavirus 2 infections, coronavirus disease 19-related emergency attendances and hospitalizations amongst older Singaporeans during an Omicron XBB wave</article-title>. <source>Clin Infect Dis</source>. <year>2023</year>;<volume>77</volume>(<issue>8</issue>):<fpage>1111</fpage>-<lpage>1119</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciad345</pub-id><pub-id pub-id-type="pmid">37280047</pub-id>
</mixed-citation></ref><ref id="zoi250398r19"><label>19</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Chong</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Wee</surname>
<given-names>LE</given-names></string-name>, <string-name><surname>Jin</surname>
<given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Risks of SARS-CoV-2 JN.1 infection and COVID-19 associated emergency-department (ED) visits/hospitalizations following updated boosters and prior infection: a population-based cohort study</article-title>. <source>Clin Infect Dis</source>. <year>2024</year>;<volume>79</volume>(<issue>5</issue>):<fpage>1190</fpage>-<lpage>1196</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciae339</pub-id><pub-id pub-id-type="pmid">38922669</pub-id>
</mixed-citation></ref><ref id="zoi250398r20"><label>20</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Wee</surname>
<given-names>LE</given-names></string-name>, <string-name><surname>Yap</surname>
<given-names>AJW</given-names></string-name>, <string-name><surname>Dickens</surname>
<given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Access to COVID-19 vaccination by socio-economic status in older Singaporean adults: a population-based cohort study</article-title>. <source>Public Health</source>. <year>2024</year>;<volume>233</volume>:<fpage>38</fpage>-<lpage>44</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.puhe.2024.05.003</pub-id><pub-id pub-id-type="pmid">38850601</pub-id>
</mixed-citation></ref><ref id="zoi250398r21"><label>21</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Hamilton</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Calzavara</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Emerson</surname>
<given-names>SD</given-names></string-name>, <etal/></person-group>. <article-title>Validating <italic>International Classification of Disease 10th Revision</italic> algorithms for identifying influenza and respiratory syncytial virus hospitalizations</article-title>. <source>PLoS One</source>. <year>2021</year>;<volume>16</volume>(<issue>1</issue>):<elocation-id>e0244746</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0244746</pub-id><pub-id pub-id-type="pmid">33411792</pub-id>
</mixed-citation></ref><ref id="zoi250398r22"><label>22</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Wee</surname>
<given-names>LE</given-names></string-name>, <string-name><surname>Lim</surname>
<given-names>JT</given-names></string-name>, <string-name><surname>Ho</surname>
<given-names>RWL</given-names></string-name>, <etal/></person-group>. <article-title>Severity of respiratory syncytial virus versus SARS-CoV-2 Omicron and influenza infection amongst hospitalized Singaporean adults: a national cohort study</article-title>. <source>Lancet Reg Health West Pac</source>. <year>2025</year>;<volume>55</volume>:<elocation-id>101494</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.lanwpc.2025.101494</pub-id><pub-id pub-id-type="pmid">40060306</pub-id>
</mixed-citation></ref><ref id="zoi250398r23"><label>23</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Wee</surname>
<given-names>LE</given-names></string-name>, <string-name><surname>Malek</surname>
<given-names>MIBA</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Risk of death and cardiovascular events following COVID-19 vaccination or positive SARS-CoV-2 test amongst adult Singaporeans during Omicron transmission</article-title>. <source>Vaccine</source>. <year>2024</year>;<volume>42</volume>(<issue>26</issue>):<elocation-id>126356</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2024.126356</pub-id><pub-id pub-id-type="pmid">39299002</pub-id>
</mixed-citation></ref><ref id="zoi250398r24"><label>24</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Lim</surname>
<given-names>JT</given-names></string-name>, <string-name><surname>Liang En</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Tay</surname>
<given-names>AT</given-names></string-name>, <etal/></person-group>. <article-title>Long-term cardiovascular, cerebrovascular, and other thrombotic complications in COVID-19 survivors: a retrospective cohort study</article-title>. <source>Clin Infect Dis</source>. <year>2024</year>;<volume>78</volume>(<issue>1</issue>):<fpage>70</fpage>-<lpage>79</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciad469</pub-id><pub-id pub-id-type="pmid">37746872</pub-id>
</mixed-citation></ref><ref id="zoi250398r25"><label>25</label><mixed-citation publication-type="journal"><person-group><string-name><surname>McCaffrey</surname>
<given-names>DF</given-names></string-name>, <string-name><surname>Griffin</surname>
<given-names>BA</given-names></string-name>, <string-name><surname>Almirall</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Slaughter</surname>
<given-names>ME</given-names></string-name>, <string-name><surname>Ramchand</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Burgette</surname>
<given-names>LF</given-names></string-name></person-group>. <article-title>A tutorial on propensity score estimation for multiple treatments using generalized boosted models</article-title>. <source>Stat Med</source>. <year>2013</year>;<volume>32</volume>(<issue>19</issue>):<fpage>3388</fpage>-<lpage>3414</lpage>. doi:<pub-id pub-id-type="doi">10.1002/sim.5753</pub-id><pub-id pub-id-type="pmid">23508673</pub-id>
</mixed-citation></ref><ref id="zoi250398r26"><label>26</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Woodruff</surname>
<given-names>RC</given-names></string-name>, <string-name><surname>Garg</surname>
<given-names>S</given-names></string-name>, <string-name><surname>George</surname>
<given-names>MG</given-names></string-name>, <etal/>; <collab>COVID-19-Associated Hospitalization Surveillance Network</collab></person-group>. <article-title>Acute cardiac events during COVID-19-associated hospitalizations</article-title>. <source>J Am Coll Cardiol</source>. <year>2023</year>;<volume>81</volume>(<issue>6</issue>):<fpage>557</fpage>-<lpage>569</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jacc.2022.11.044</pub-id><pub-id pub-id-type="pmid">36754516</pub-id>
</mixed-citation></ref><ref id="zoi250398r27"><label>27</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Surie</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Yuengling</surname>
<given-names>KA</given-names></string-name>, <string-name><surname>DeCuir</surname>
<given-names>J</given-names></string-name>, <etal/>; <collab>Investigating Respiratory Viruses in the Acutely Ill (IVY) Network</collab></person-group>. <article-title>Severity of respiratory syncytial virus vs COVID-19 and influenza among hospitalized US adults</article-title>. <source>JAMA Netw Open</source>. <year>2024</year>;<volume>7</volume>(<issue>4</issue>):<elocation-id>e244954</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.4954</pub-id><pub-id pub-id-type="pmid">38573635</pub-id>
</mixed-citation></ref><ref id="zoi250398r28"><label>28</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Sepp&#x000e4;l&#x000e4;</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Dahl</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Veneti</surname>
<given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: a population-based cohort study, 3 October 2022 to 20 June 2023</article-title>. <source>Vaccine</source>. <year>2024</year>;<volume>42</volume>(<issue>3</issue>):<fpage>620</fpage>-<lpage>628</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2023.12.050</pub-id><pub-id pub-id-type="pmid">38142215</pub-id>
</mixed-citation></ref><ref id="zoi250398r29"><label>29</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Eisenhut</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Sidaras</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Johnson</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Newland</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Thorburn</surname>
<given-names>K</given-names></string-name></person-group>. <article-title>Cardiac troponin T levels and myocardial involvement in children with severe respiratory syncytial virus lung disease</article-title>. <source>Acta Paediatr</source>. <year>2004</year>;<volume>93</volume>(<issue>7</issue>):<fpage>887</fpage>-<lpage>890</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1651-2227.2004.tb02685.x</pub-id><pub-id pub-id-type="pmid">15303802</pub-id>
</mixed-citation></ref><ref id="zoi250398r30"><label>30</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Esposito</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Salice</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Bosis</surname>
<given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Altered cardiac rhythm in infants with bronchiolitis and respiratory syncytial virus infection</article-title>. <source>BMC Infect Dis</source>. <year>2010</year>;<volume>10</volume>:<fpage>305</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1471-2334-10-305</pub-id><pub-id pub-id-type="pmid">20969802</pub-id>
</mixed-citation></ref><ref id="zoi250398r31"><label>31</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Eisenhut</surname>
<given-names>M</given-names></string-name></person-group>. <article-title>Extrapulmonary manifestations of severe respiratory syncytial virus infection&#x02013;a systematic review</article-title>. <source>Crit Care</source>. <year>2006</year>;<volume>10</volume>(<issue>4</issue>):<fpage>R107</fpage>. doi:<pub-id pub-id-type="doi">10.1186/cc4984</pub-id><pub-id pub-id-type="pmid">16859512</pub-id>
</mixed-citation></ref><ref id="zoi250398r32"><label>32</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Wee</surname>
<given-names>LE</given-names></string-name>, <string-name><surname>Lim</surname>
<given-names>JT</given-names></string-name>, <string-name><surname>Tay</surname>
<given-names>AT</given-names></string-name>, <etal/></person-group>. <article-title>Long-term cardiovascular, cerebrovascular, and thrombotic complications after SARS-CoV-2-Omicron infection: a retrospective cohort study</article-title>. <source>Clin Microbiol Infect</source>. <year>2024</year>;<volume>30</volume>(<issue>10</issue>):<fpage>1319</fpage>-<lpage>1326</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cmi.2024.06.011</pub-id><pub-id pub-id-type="pmid">38908748</pub-id>
</mixed-citation></ref><ref id="zoi250398r33"><label>33</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Wee</surname>
<given-names>LE</given-names></string-name>, <string-name><surname>Lim</surname>
<given-names>JT</given-names></string-name>, <string-name><surname>Tay</surname>
<given-names>AT</given-names></string-name>, <etal/></person-group>. <article-title>Long-term neuropsychiatric sequelae of Delta versus Omicron SARS-CoV-2 infection</article-title>. <source>Clin Microbiol Infect</source>. <year>2024</year>;<volume>30</volume>(<issue>4</issue>):<fpage>531</fpage>-<lpage>539</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cmi.2023.12.019</pub-id><pub-id pub-id-type="pmid">38141822</pub-id>
</mixed-citation></ref><ref id="zoi250398r34"><label>34</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Carrico</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Hicks</surname>
<given-names>KA</given-names></string-name>, <string-name><surname>Wilson</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Panozzo</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Ghaswalla</surname>
<given-names>P</given-names></string-name></person-group>. <article-title>The annual economic burden of respiratory syncytial virus in adults in the United States</article-title>. <source>J Infect Dis</source>. <year>2024</year>;<volume>230</volume>(<issue>2</issue>):<fpage>e342</fpage>-<lpage>e352</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jiad559</pub-id><pub-id pub-id-type="pmid">38060972</pub-id>
</mixed-citation></ref><ref id="zoi250398r35"><label>35</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Tan</surname>
<given-names>RY</given-names></string-name>, <string-name><surname>Wong</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Lim</surname>
<given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Factors associated with delayed diagnosis of symptomatic adult COVID-19 cases presenting to primary care: a population-wide study during transition from Delta to Omicron BA.1 in Singapore</article-title>. <source>Lancet Reg Health West Pac</source>. <year>2023</year>;<volume>41</volume>:<elocation-id>100919</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.lanwpc.2023.100919</pub-id><pub-id pub-id-type="pmid">37780634</pub-id>
</mixed-citation></ref><ref id="zoi250398r36"><label>36</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Tan</surname>
<given-names>RY</given-names></string-name>, <string-name><surname>Dickens</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Oral antiviral utilisation among older adults with COVID-19 in primary care: a population-wide study during successive Omicron waves in Singapore</article-title>. <source>Ann Acad Med Singap</source>. <year>2024</year>;<volume>53</volume>(<issue>2</issue>):<fpage>117</fpage>-<lpage>120</lpage>. doi:<pub-id pub-id-type="doi">10.47102/annals-acadmedsg.2023297</pub-id><pub-id pub-id-type="pmid">38920236</pub-id>
</mixed-citation></ref><ref id="zoi250398r37"><label>37</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Wee</surname>
<given-names>LE</given-names></string-name>, <string-name><surname>Tay</surname>
<given-names>AT</given-names></string-name>, <string-name><surname>Chiew</surname>
<given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission</article-title>. <source>Clin Microbiol Infect</source>. <year>2023</year>;<volume>29</volume>(<issue>10</issue>):<fpage>1328</fpage>-<lpage>1333</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cmi.2023.06.016</pub-id><pub-id pub-id-type="pmid">37331509</pub-id>
</mixed-citation></ref><ref id="zoi250398r38"><label>38</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Tippett</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ess</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Hussaini</surname>
<given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Influenza vaccine effectiveness pre-pandemic among adults hospitalized with congestive heart failure or chronic obstructive pulmonary disease and older adults</article-title>. <source>Clin Infect Dis</source>. <year>2024</year>;<volume>78</volume>(<issue>4</issue>):<fpage>1065</fpage>-<lpage>1072</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciad679</pub-id><pub-id pub-id-type="pmid">37946601</pub-id>
</mixed-citation></ref><ref id="zoi250398r39"><label>39</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Mir&#x000f3;</surname>
<given-names>&#x000d2;</given-names></string-name>, <string-name><surname>Ivars</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Espinosa</surname>
<given-names>B</given-names></string-name>, <etal/>; <collab>ICA-SEMES group</collab></person-group>. <article-title>Effect of seasonal influenza and COVID-19 vaccination on severity and long-term outcomes of patients with heart failure decompensations</article-title>. <source>Eur J Heart Fail</source>. <year>2025</year>;<volume>27</volume>(<issue>1</issue>):<fpage>152</fpage>-<lpage>165</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ejhf.3469</pub-id><pub-id pub-id-type="pmid">39315591</pub-id>
</mixed-citation></ref><ref id="zoi250398r40"><label>40</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Begley</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Monto</surname>
<given-names>AS</given-names></string-name>, <string-name><surname>Lamerato</surname>
<given-names>LE</given-names></string-name>, <etal/></person-group>. <article-title>Prevalence and clinical outcomes of respiratory syncytial virus vs influenza in adults hospitalized with acute respiratory illness from a prospective multicenter study</article-title>. <source>Clin Infect Dis</source>. <year>2023</year>;<volume>76</volume>(<issue>11</issue>):<fpage>1980</fpage>-<lpage>1988</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciad031</pub-id><pub-id pub-id-type="pmid">36694363</pub-id>
</mixed-citation></ref><ref id="zoi250398r41"><label>41</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Biegus</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Szenborn</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Zymli&#x00144;ski</surname>
<given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>The early safety profile of simultaneous vaccination against influenza and respiratory syncytial virus (RSV) in patients with high-risk heart failure</article-title>. <source>Vaccine</source>. <year>2024</year>;<volume>42</volume>(<issue>12</issue>):<fpage>2937</fpage>-<lpage>2940</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2024.03.060</pub-id><pub-id pub-id-type="pmid">38531725</pub-id>
</mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-ZOI250398-1"><supplementary-material id="note-ZOI250398-1-s" position="float" content-type="local-data"><label>Supplement 1.</label><caption><p><bold>eTable 1.</bold> Factors associated with occurrence of acute cardiovascular events amongst hospitalisations for respiratory-syncytial-virus in Singaporean adults</p><p><bold>eTable 2.</bold> Factors associated with occurrence of acute cardiovascular events amongst hospitalisations for influenza in Singaporean adults</p><p><bold>eTable 3.</bold> Factors associated with occurrence of acute cardiovascular events amongst hospitalisations for Omicron XBB/JN.1 SARS-CoV-2 in Singaporean adults</p><p><bold>eTable 4.</bold> Sociodemographic and clinical characteristics of hospitalisations for respiratory-syncytial-virus, influenza and Omicron XBB/JN.1 SARS-CoV-2 in Singaporean adults aged&#x02265;60 years</p><p><bold>eTable 5.</bold> Prevalence of acute cardiovascular events (composite) amongst hospitalisations for respiratory-syncytial-virus, influenza and Omicron XBB/JN.1 SARS-CoV-2 in Singaporean adults aged&#x02265;60 years</p><p><bold>eTable 6.</bold> Prevalence of acute cardiovascular events (individual) amongst hospitalisations for respiratory-syncytial-virus, influenza and Omicron XBB/JN.1 SARS-CoV-2 in Singaporean adults aged&#x02265;60 years</p><p><bold>eTable 7.</bold> Odds of intensive-care-unit (ICU) admission, stratified by presence of an acute cardiovascular event, during acute hospitalisations for respiratory-syncytial-virus, influenza and Omicron XBB/JN.1 SARS-CoV-2 in Singaporean adults aged&#x02265;60 years</p><p><bold>eTable 8.</bold> Sociodemographic and clinical characteristics of contemporaneous hospitalisations during 2023-2024 for respiratory-syncytial-virus, influenza and Omicron XBB/JN.1 SARS-CoV-2 in Singaporean adults</p><p><bold>eTable 9.</bold> Prevalence of acute cardiovascular events (composite) amongst contemporaneous hospitalisations during 2023-2024 for respiratory-syncytial-virus, influenza and Omicron XBB/JN.1 SARS-CoV-2 in Singaporean adults</p><p><bold>eTable 10.</bold> Prevalence of acute cardiovascular events (individual) amongst contemporaneous hospitalisations during 2023-2024 for respiratory-syncytial-virus, influenza and Omicron XBB/JN.1 SARS-CoV-2 in Singaporean adults</p><p><bold>eTable 11.</bold> Odds of intensive-care-unit (ICU) admission, stratified by presence of an acute cardiovascular event, amongst contemporaneous acute hospitalisations during 2023-2024 for respiratory-syncytial-virus, influenza and Omicron XBB/JN.1 SARS-CoV-2 in Singaporean adults</p><p><bold>eTable 12.</bold> Prevalence of acute cardiovascular events (composite) amongst hospitalisations for respiratory-syncytial-virus versus PCR- confirmed Omicron XBB/JN.1 SARS-CoV-2 in Singaporean adults</p><p><bold>eTable 13.</bold> Prevalence of acute cardiovascular events (individual) amongst hospitalisations for respiratory-syncytial-virus versus PCR-confirmed Omicron XBB/JN.1 SARS-CoV-2 in Singaporean adults</p><p><bold>eAppendix.</bold> List of ICD-10 codes used for outcomes of interest</p></caption><media xlink:href="jamanetwopen-e2511764-s001.pdf"/></supplementary-material><supplementary-material position="float" content-type="local-data"><label>Supplement 2.</label><caption><p>
Data Sharing Statement
</p></caption><media xlink:href="jamanetwopen-e2511764-s002.pdf"/></supplementary-material></notes></back></article><!--requester-ID gmcconne-->